Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (scientific article (publication date: 20 May 2004))

cites work (P2860)

Q64235327	Q64235327
Q40251406	"Lineage addiction" in human cancer: lessons from integrated genomics
Q35570245	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Q36883649	"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Q36610717	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
Q37253248	(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib
Q37112466	(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Q53558235	+61A>G polymorphism in the EGF gene does not increase the risk of lung cancer.
Q37211807	-216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma
Q38390111	10(th) Congress on Lung Cancer-updates on clinical trials: goal
Q50759853	10th annual meeting--Association for Molecular Pathology.
Q37605725	18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
Q37616082	2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
Q45017925	2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
Q29998998	2004: Signaling Breakthroughs of the Year
Q37937877	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy
Q48543939	226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.
Q36688956	244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
Q33937876	3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants
Q34317305	3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer
Q39123460	5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Q27014978	50 Years of progress in the systemic therapy of non-small cell lung cancer
Q35992488	7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.
Q37371303	A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity
Q38778226	A Histologic Basis for the Efficacy of SBRT to the lung
Q36197300	A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element
Q37742623	A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
Q41738897	A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma
Q36028935	A Novel Technique to Detect EGFR Mutations in Lung Cancer.
Q54976886	A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC.
Q37126741	A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer
Q36138130	A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features
Q88088348	A REVELation in non-small-cell lung cancer treatment?
Q92281107	A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations
Q42726924	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs
Q47557191	A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib and Afatinib in Japanese Patients with Non-small Cell Lung Cancer
Q53138132	A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Q35971883	A Screening Method for the ALK Fusion Gene in NSCLC.
Q35463464	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer
Q36445112	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans
Q58701423	A catalogue of somatic NRF2 gain-of-function mutations in cancer
Q33742159	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Q27851729	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
Q37169157	A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes
Q41574578	A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients
Q34405695	A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry
Q47648174	A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component
Q51054715	A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers.
Q91799952	A comprehensive review of protein kinase inhibitors for cancer therapy
Q36488342	A critical appraisal of prognostic and predictive factors for common lung cancers.
Q26797297	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Q33747412	A decade of chemical biology
Q64885162	A driving test for oncogenic mutations.
Q35906737	A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B.
Q36342432	A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Q61866333	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Q37596247	A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
Q33978771	A gene-alteration profile of human lung cancer cell lines.
Q34523304	A genetic basis for the variation in the vulnerability of cancer to DNA damage
Q38717620	A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
Q39123357	A genomics-based classification of human lung tumors
Q36062442	A growing family: adding mutated Erbb4 as a novel cancer target
Q39112227	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
Q42290335	A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer
Q37945265	A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Q30603151	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population
Q37765591	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
Q40289611	A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
Q47590798	A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Q55363674	A microfluidics platform for combinatorial drug screening on cancer biopsies.
Q58693828	A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction
Q30485093	A mouse model for EML4-ALK-positive lung cancer
Q36383409	A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
Q34492884	A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations
Q35805662	A mutation-sensitive switch assay to detect five clinically significant epidermal growth factor receptor mutations
Q36636641	A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy
Q38433965	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine
Q35072998	A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer
Q46597381	A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer
Q36010772	A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors
Q34980292	A novel five-antibody immunohistochemical test for subclassification of lung carcinoma
Q51553861	A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA.
Q37148645	A novel information retrieval model for high-throughput molecular medicine modalities
Q89989597	A novel loop‑mediated isothermal amplification method for efficient and robust detection of EGFR mutations
Q28486089	A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer
Q33265633	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
Q60915049	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
Q35757512	A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII.
Q41507784	A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system
Q39467165	A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance
Q33699169	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
Q35872687	A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
Q28069867	A perspective on anti-EGFR therapies targeting triple-negative breast cancer
Q37411548	A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment
Q54645672	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Q80101024	A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer
Q36206894	A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer
Q37217268	A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
Q33619858	A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors
Q36748775	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
Q34399739	A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
Q44290350	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
Q37423291	A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
Q57975564	A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
Q34722457	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium
Q33422429	A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
Q36614353	A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
Q35093305	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia
Q79382565	A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies
Q37357251	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
Q34571839	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
Q84814758	A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
Q46577596	A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Q46640878	A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Q46041319	A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
Q46916475	A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
Q50309092	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Q47804358	A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers
Q34478770	A pilot characterization of human lung NSCLC by protein pathway activation mapping
Q34192568	A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer
Q33994726	A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance
Q36814881	A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
Q34760642	A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer
Q36728796	A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
Q36224203	A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer
Q37528312	A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting
Q42371546	A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer
Q28472058	A predictive phosphorylation signature of lung cancer
Q35790221	A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.
Q34924658	A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients
Q37483162	A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments
Q38174702	A review of economic impact of targeted oral anticancer medications.
Q36376408	A review of erlotinib and its clinical use.
Q34164735	A review on various targeted anticancer therapies
Q50294553	A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients.
Q51062307	A robustness-based approach to systems-oriented drug design.
Q33943860	A short in-frame deletion in NTRK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensitivity to pain with anhidrosis
Q38253576	A short update on cancer chemoresistance
Q33947516	A simple and cost-effective method of DNA extraction from small formalin-fixed paraffin-embedded tissue for molecular oncologic testing
Q47712658	A single-round selection of selective DNA aptamers for mammalian cells by polymer-enhanced capillary transient isotachophoresis.
Q29617451	A small molecule-kinase interaction map for clinical kinase inhibitors
Q30364303	A spatial simulation approach to account for protein structure when identifying non-random somatic mutations
Q85582758	A step towards treating KRAS-mutant NSCLC
Q54114458	A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study.
Q38806879	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
Q33577844	A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice
Q35791529	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Q34733314	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells
Q28487847	A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer
Q34952878	A two-step toward personalized therapies for prostate cancer
Q34979703	A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma
Q46603388	A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial
Q46752829	AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
Q37373040	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Q92783310	ADAM17: An Emerging Therapeutic Target for Lung Cancer
Q38689104	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future
Q28550038	AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
Q57074582	ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
Q28393324	ALK and NSCLC: Targeted therapy with ALK inhibitors
Q90158888	ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital
Q28083386	ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it
Q36836809	ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Q34431889	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond
Q38074590	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Q52366358	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.
Q38095630	ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer
Q34162940	ALK-activating homologous mutations in LTK induce cellular transformation
Q36866859	ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Q28479059	AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo
Q36081033	AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Q35632590	AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827.
Q54494486	AXL and acquired resistance to EGFR inhibitors.
Q27853013	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Q37304950	Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry
Q36839797	Aberrant kinase signaling: lessons from head and neck cancer
Q35607826	Aberrant signaling pathways in squamous cell lung carcinoma
Q30931456	Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.
Q33947959	Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Q54561321	Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Q34809743	Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis
Q30439629	Absence of AKT1 mutations in glioblastoma
Q46930154	Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients
Q57494704	Abstracts from the European Respiratory Society Annual Conference 2018 on Thoracic Oncology
Q49962868	Academic medical centers as innovation ecosystems to address population -omics challenges in precision medicine.
Q57060148	Accelerating anticancer drug development - opportunities and trade-offs
Q53309943	Accuracy and sensitivity of computed tomography-guided percutaneous needle biopsy of pulmonary hilar lymph nodes.
Q33378925	Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients
Q102060844	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome
Q38824661	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
Q27678436	Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
Q53701267	Acquired Resistance to Drugs Targeting Tyrosine Kinases.
Q39223532	Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.
Q24816331	Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R
Q24794765	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Q39173405	Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
Q36726112	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
Q37623870	Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss
Q35823437	Acquired resistance to drugs targeting receptor tyrosine kinases
Q37000611	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
Q37379113	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Q43237713	Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications
Q36910173	Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants
Q30513309	Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy.
Q36262907	Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
Q31119684	Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma
Q35828697	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Q55281801	Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model.
Q46048353	Activated Akt prevents antitumor activity of gefitinib in renal cancer cells
Q56032135	Activated Stat-3 in Melanoma
Q93388156	Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression
Q27851987	Activating HER2 mutations in HER2 gene amplification negative breast cancer
Q33769838	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Q84634790	Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality
Q27851452	Activating mutations in ALK provide a therapeutic target in neuroblastoma
Q38494311	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
Q36676421	Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer
Q36005545	Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Q34463388	Activation of RAS family members confers resistance to ROS1 targeting drugs.
Q40176065	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
Q36128435	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Q39346046	Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".
Q37225463	Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
Q33636907	Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells
Q45141063	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
Q36970403	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
Q38363739	Adaptive stress signaling in targeted cancer therapy resistance
Q35608002	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
Q25254985	Adding pharmacogenomics to the development of new marine-derived anticancer agents
Q33922925	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Q96685864	Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas
Q38766913	Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
Q38329647	Addressing the right targets in oncology: challenges and alternative approaches
Q54595873	Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.
Q36503280	Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma.
Q48221075	Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment
Q43073804	Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
Q36521844	Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future
Q37777311	Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
Q38390085	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond
Q39012785	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).
Q35076202	Adjuvant therapy for resected non-small cell lung cancer
Q46979111	Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Q27021203	Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations
Q46652808	Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study.
Q37576481	Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
Q37687540	Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
Q38153446	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
Q38948499	Advances and challenges in hereditary cancer pharmacogenetics
Q38526025	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma
Q90477429	Advances in Non-invasive Neurodiagnostics
Q36112651	Advances in Proteomic Technologies and Its Contribution to the Field of Cancer
Q34031225	Advances in adjuvant systemic therapy for non-small-cell lung cancer
Q90345837	Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
Q38127786	Advances in personalized therapy for lung cancer
Q37661928	Advances in target therapy for lung cancer
Q39220897	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
Q30014827	Advances in understanding cancer genomes through second-generation sequencing
Q35200375	Advances on EGFR mutation for lung cancer
Q38148583	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Q34803010	Advancing clinical oncology through genome biology and technology.
Q53263258	Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice.
Q58925880	Aetiology: Crucial clues
Q33649260	Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways.
Q38270627	Afatinib and lung cancer.
Q27851751	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
Q36132436	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.
Q28082181	Afatinib for the treatment of metastatic non-small cell lung cancer
Q35273471	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A
Q91328931	Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)
Q27852787	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Q38809376	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Q38646686	Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress
Q42465729	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
Q39663675	Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases
Q88682212	Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer
Q38805618	Alectinib for treatment of ALK-positive non-small-cell lung cancer
Q90814523	Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
Q40437197	Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity
Q55104021	Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
Q52087873	Aligning the stakeholders.
Q91949987	All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
Q24811573	Allele-specific amplification in cancer revealed by SNP array analysis
Q27851396	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Q92633975	Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
Q38465098	Allosteric therapies for lung cancer
Q36973814	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
Q51072877	Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
Q36669872	Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
Q37724576	Alterations in VHL as potential biomarkers in renal-cell carcinoma
Q51503951	Alterations in cathepsin L expression in lung cancers.
Q33411775	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
Q42002748	Altered trafficking of mutated growth factor receptors and their associated molecules: implication for human cancers
Q34535276	Alveolar type II cells possess the capability of initiating lung tumor development
Q54124211	Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis.
Q33731181	Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Q35964699	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers
Q24541450	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Q41837923	Amplification of chromosome 8 genes in lung cancer
Q48462937	Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.
Q46906937	Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Q47116010	Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report
Q36228469	An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
Q42695763	An Architecture for Genomics Analysis in a Clinical Setting Using Galaxy and Docker
Q33890958	An EGFR autocrine loop encodes a slow-reacting but dominant mode of mechanotransduction in a polarized epithelium.
Q37137440	An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).
Q47135621	An Immunohistochemical Study of Anaplastic Lymphoma Kinase and Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Carcinoma
Q64053000	An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer
Q39009616	An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
Q24293598	An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Q39684120	An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
Q53287085	An early event of EGFR mutation in pleomorphic carcinoma of the lung.
Q53139955	An epidermal growth factor receptor exon 19 mutation in a mucin-producing gastric cancer sample from a Chinese patient.
Q54634908	An epidermal growth factor receptor intron 1 polymorphism in healthy women in Poland.
Q36597042	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
Q53158256	An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.
Q37690880	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
Q55053711	An improved cell membrane chromatography method for the simultaneous screening of two epidermal growth factor receptor antagonists from radix scutellariae.
Q40783190	An in silico analytical study of lung cancer and smokers datasets from gene expression omnibus (GEO) for prediction of differentially expressed genes
Q35237394	An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
Q35872681	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
Q48165470	An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Q53587222	An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.
Q44736272	An overview of Cancer's special issue on lung cancer in China
Q36043195	An overview of lung cancer genomics and proteomics
Q92884879	An unbiased in vitro screen for activating epidermal growth factor receptor mutations
Q38077494	An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
Q34857289	Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities
Q42551719	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer.
Q36439434	Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients
Q46408397	Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma
Q33598423	Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer
Q39371891	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients
Q35058437	Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Q39308117	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors
Q88729591	Analysis of circulating tumor DNA: The next paradigm shift in detection and treatment of lung cancer
Q28472663	Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
Q26797471	Analysis of different HER-2 mutations in breast cancer progression and drug resistance
Q50936062	Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Q34522964	Analysis of growth factor signaling in genetically diverse breast cancer lines
Q37702099	Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.
Q37119867	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
Q50947169	Analytic inquiry: Molecular testing in lung cancer.
Q41348195	Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report
Q37952236	Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Q54367113	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Q27851588	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
Q50955739	Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer.
Q34283623	Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
Q36104939	Angiogenesis and prostate cancer: important laboratory and clinical findings
Q57023042	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Q35631966	Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays
Q53121293	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Q38832105	Anti-EGFR Agents: Current Status, Forecasts and Future Directions.
Q38876644	Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Q34088265	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Q36321894	Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity
Q37293327	Anti-epidermal growth factor receptor strategies for advanced breast cancer
Q28729071	Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells
Q41612476	Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification
Q38086799	Anti-vascular endothelial growth factor therapy in the era of personalized medicine
Q55509033	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase.
Q34132010	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.
Q46836125	Antibody-based targeted therapy for gastric cancer
Q40133703	Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Q36466443	Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm
Q36612420	Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
Q90283381	Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
Q39980200	Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo
Q36448279	Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models
Q36413281	Antrodia cinnamomea alleviates cisplatin-induced hepatotoxicity and enhances chemo-sensitivity of line-1 lung carcinoma xenografted in BALB/cByJ mice.
Q64070319	Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
Q37605160	Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics
Q35480110	Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells
Q27016160	Apoptotic agents
Q33235709	Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family
Q37197507	Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients
Q64099108	Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
Q38170457	Application of genotype-guided cancer therapy in solid tumors
Q37204679	Applications of genomics in melanoma oncogene discovery
Q36753505	Applications of molecular techniques to fine-needle aspiration biopsy
Q33687963	Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma
Q36900109	Applying the discovery of the Philadelphia chromosome
Q36045981	Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor
Q36502531	Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study
Q38989374	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
Q37564967	Are TKIs favourable for the elderly with non-small-cell lung cancer?
Q37351965	Are We Making Personalized Cancer Care Less Personalized?
Q37976288	Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Q33555207	Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine
Q35535953	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
Q43061603	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors
Q42204388	Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
Q36946796	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer
Q35584933	Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes
Q37121410	Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer
Q37052272	Assessment of epidermal growth factor receptor status in glioblastomas
Q53126969	Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.
Q55299188	Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib.
Q37274280	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Q53094070	Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Q54965644	Assessment of very early response evaluation with 18F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods.
Q28550377	Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Q64983153	Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer.
Q90221713	Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
Q36526428	Association between GABA(A) receptor subunit gene cluster and zolpidem-induced complex sleep behaviors in Han Chinese.
Q40406762	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations
Q43131701	Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer
Q83856059	Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma
Q54520157	Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Q37569995	Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.
Q89602661	Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression
Q54310972	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
Q37641038	Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer
Q27851860	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
Q54343399	Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Q53269068	Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
Q41862336	Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients
Q40080780	Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases
Q90335241	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Q47764617	Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients
Q36337437	Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation
Q43265336	Attacking cancer at its foundation
Q58804389	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Q35583019	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers
Q38960732	Automated objective determination of percentage of malignant nuclei for mutation testing
Q35014385	Awakening guardian angels: drugging the p53 pathway
Q37738168	B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
Q104475963	BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
Q37841599	BIBW 2992 in non-small cell lung cancer
Q24649935	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Q37708873	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
Q35588268	BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Q28756824	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
Q36413639	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
Q42733647	BRAF targeted therapy changes the treatment paradigm in melanoma
Q92284666	Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
Q64913573	Basic science of lung cancer.
Q33218734	Basics of molecular diagnostics and therapy of malignant tumors
Q50095063	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Q36011788	Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology
Q28740430	Benchmarking of mutation diagnostics in clinical lung cancer specimens
Q59808313	Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Q92218750	Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells
Q47142558	Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer
Q36832129	Bevacizumab in the treatment of non-small-cell lung cancer
Q37001902	Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
Q35025931	Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models
Q46512789	Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer
Q38569159	Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses.
Q33560928	Beyond histology: translating tumor genotypes into clinically effective targeted therapies
Q40340043	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Q50288609	Binding of GRB2:GAB1 complex to ligand-responsive p-6Y-EGFR mutants
Q50288599	Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants
Q46963924	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients
Q38386392	Biobanking for Personalized Medicine
Q37665845	Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors
Q59335693	Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway
Q35885829	Bioinformatics and cancer target discovery
Q81367068	Biologic staging of non-small-cell lung cancer: prospect or proposal?
Q37242685	Biologic therapies for advanced pancreatic cancer
Q36521850	Biological agents versus chemotherapy in the treatment of colorectal cancer
Q36540571	Biological and clinical implications of EGFR mutations in lung cancer.
Q45965455	Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Q34094855	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Q34248282	Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers
Q34023414	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
Q39181810	Biomarkers and Immunotherapeutic Targets in Glioblastoma
Q36260477	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
Q37988924	Biomarkers and transcriptome profiling of lung cancer
Q37692666	Biomarkers in bronchopulmonary cancer
Q28278305	Biomarkers in cancer staging, prognosis and treatment selection
Q37006905	Biomarkers in drug discovery and development
Q37371586	Biomarkers in early cancer drug development: limited utility
Q34094906	Biomarkers of acute lung injury: worth their salt?
Q39569308	Biomarkers of cancer metastasis through the lymphovascular system: future perspectives
Q35108419	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
Q26766535	Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
Q36040606	Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS
Q47110241	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.
Q37388387	Biopsy and mutation detection strategies in non-small cell lung cancer
Q90697012	Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience
Q37236777	BlackOPs: increasing confidence in variant detection through mappability filtering
Q36842495	Blood-brain barrier transport of non-viral gene and RNAi therapeutics
Q36477753	Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Q35154082	Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation
Q33989444	Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway
Q36224108	Braf and erbB2 mutations correlate with smoking status in lung cancer patients
Q48569495	Brain metastases from non-small-cell lung cancer: is there room for improvement?
Q38233149	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches
Q64071943	Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
Q41846992	Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
Q48044475	Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung
Q50949344	Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma.
Q37028777	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Q60097206	Broken genes in solid tumours
Q41643045	Bronchioloalveolar neoplasia.
Q39941747	Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer
Q36929987	Building a personalized medicine infrastructure at a major cancer center
Q38385958	Building the foundation for genomics in precision medicine
Q35176335	By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer
Q37421439	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer
Q34031219	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Q35962454	CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice
Q34342934	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Q55072491	CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Q54673900	CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Q35778685	CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells
Q27310110	CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.
Q46979383	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation
Q38924458	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations.
Q33808203	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Q36525874	CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy
Q38614582	CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer
Q41751613	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
Q60301839	CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study
Q41997242	CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
Q100416116	CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas
Q89116459	CT features of HER2-mutant lung adenocarcinomas
Q35086187	CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool
Q36615733	CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy
Q37352553	CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
Q61806215	Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
Q35537522	Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Q36427587	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis
Q26999304	Can microRNAs improve the management of lung cancer patients? A clinician's perspective
Q34986181	Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation
Q53243032	Cancer Genomics.
Q35999625	Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care
Q37153533	Cancer as a system failure
Q37810056	Cancer biology and genomics: translating discoveries, transforming pathology
Q36561609	Cancer biomarkers: a systems approach
Q42968372	Cancer biomarkers: closer to delivering on their promise
Q27010961	Cancer concepts and principles: primer for the interventional oncologist-part II
Q34002709	Cancer driver mutations in protein kinase genes
Q36111899	Cancer drug discovery through collaboration.
Q37399404	Cancer epigenomics: implications of DNA methylation in personalized cancer therapy
Q28275089	Cancer genes and the pathways they control
Q36481954	Cancer genes in lung cancer: racial disparities: are there any?
Q38180646	Cancer genomics and inherited risk
Q34301519	Cancer genomics and pathology: all together now.
Q63018119	Cancer genomics: from discovery science to personalized medicine
Q35583180	Cancer immunology--analysis of host and tumor factors for personalized medicine
Q36822291	Cancer pharmacogenomics
Q26741009	Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Q24289309	Cancer pharmacogenomics: strategies and challenges
Q90372559	Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2
Q36359653	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations
Q38028798	Cancer treatment according to BRCA1 and BRCA2 mutations
Q44574128	Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins
Q44960549	Cancer: understanding the target
Q36385644	Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
Q36092823	Carcinogenesis, cancer therapy and chemoprevention
Q33249923	Carcinosarcoma of the colon: report of a case with morphological, ultrastructural and molecular analysis
Q37061596	Cardiac toxicity: old and new issues in anti-cancer drugs.
Q33807542	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives
Q93203400	Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
Q53631481	Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas.
Q39205831	Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells.
Q35219426	Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.
Q38268502	Catalytic mechanisms and regulation of protein kinases
Q91805218	Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models
Q24598357	Cell signaling by receptor tyrosine kinases
Q52361534	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.
Q41431886	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
Q34789161	Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
Q81939291	Cell-free DNA resuscitated for tumor testing
Q38263419	Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
Q36003118	Cellular responses to EGFR inhibitors and their relevance to cancer therapy
Q38214154	Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer
Q36171281	Cetuximab and biomarkers in non-small-cell lung carcinoma
Q35023512	Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).
Q36668224	Cetuximab in the treatment of head and neck cancer
Q46261715	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Q41894424	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
Q36832116	Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
Q98292342	Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
Q44948356	Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours
Q88790405	Challenges and opportunities of pharmacogenetics in drug development
Q34608597	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System
Q37220383	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
Q38947180	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Q37177604	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
Q35179046	Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease
Q34225871	Change or die: targeting adaptive signaling to kinase inhibition in cancer cells
Q26774513	Changing strategies for target therapy in gastric cancer
Q36849676	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma
Q34778365	Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART.
Q28706226	Characteristics of lung cancers harboring NRAS mutations
Q51661151	Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients.
Q55317607	Characterization of Covalent-Reversible EGFR Inhibitors.
Q36389868	Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer
Q58786657	Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA
Q36248587	Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity
Q92164128	Characterization of cancer omics and drug perturbations in panels of lung cancer cells
Q47139649	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
Q43056671	Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas
Q27317429	Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling
Q37004639	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
Q64058283	Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape
Q36185641	Chemoprevention of lung cancer: concepts and strategies
Q46936682	Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis
Q36989648	Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer
Q37799220	Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?
Q37614566	Chemotherapy for lung cancer: the state of the art in 2009.
Q40375603	Chemotherapy for metastatic NSCLC: current status and future direction
Q38237655	Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel)
Q38838014	Chemotherapy remains an essential element of personalized care for persons with lung cancers
Q30940337	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data
Q82297408	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas
Q35217204	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells
Q39869486	Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays
Q34198721	Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer
Q36223578	Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities
Q33781119	Chromosomal and genomic changes in lung cancer
Q41487356	Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis
Q42453112	Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation
Q35837368	Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations
Q37641586	Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells
Q36287400	Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c
Q52640291	Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs.
Q35207885	Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.
Q36309536	Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition
Q38232303	Ciliated muconodular papillary tumor of the lung: a newly defined peripheral pulmonary tumor with conspicuous mucin pool mimicking colloid adenocarcinoma: a case report and review of literature
Q36834331	Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease
Q37635310	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
Q37780014	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.
Q33640472	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Q28077340	Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?
Q37673460	Circulating tumor cells: a window into cancer biology and metastasis
Q24631347	Circulating tumor cells: approaches to isolation and characterization
Q37000646	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Q39169544	Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes
Q38043495	Citation classics: Top 50 cited articles in 'respiratory system'.
Q38262804	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Q50050455	Classification and regression tree analysis of patients with non-small-cell lung cancer treated with gefitinib after chemotherapy.
Q35654703	Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer
Q38574971	Classification of different patterns of pulmonary adenocarcinomas.
Q52888052	Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
Q47168748	Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib
Q36613044	Clinical Next Generation Sequencing for Precision Medicine in Cancer
Q57214546	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Q36238822	Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
Q27853182	Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Q38270195	Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
Q38519252	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Q43195843	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer
Q37455251	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Q29615475	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Q64098526	Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer
Q38042709	Clinical and economic review of erlotinib in non-small-cell lung cancer
Q34952066	Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung
Q46815372	Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Q55003763	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
Q40048521	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions
Q38402811	Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
Q38065062	Clinical applications for microRNAs in cancer
Q36111249	Clinical applications for targeted therapy in bladder cancer
Q36311991	Clinical applications of genomics in head and neck cancer
Q38504491	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Q36628704	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk
Q46446185	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program
Q33279462	Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Q37523898	Clinical biomarkers in oncology: focus on colorectal cancer
Q37815145	Clinical cancer genomics: how soon is now?
Q38253280	Clinical cancer research: the past, present and the future
Q34610381	Clinical characteristics and course of 63 patients with BRAF mutant lung cancers
Q41920066	Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy
Q54109548	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Q35023498	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations
Q42780600	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
Q36031642	Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial
Q35566234	Clinical development of phosphatidylinositol-3 kinase pathway inhibitors
Q64055605	Clinical development of targeted and immune based anti-cancer therapies
Q44634377	Clinical development of targeted moledular cancer drugs
Q33742964	Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
Q46552225	Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride
Q49720695	Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.
Q90353311	Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
Q48422999	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Q35681021	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer
Q29615472	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
Q33779181	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
Q37220488	Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer
Q53303546	Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Q37317171	Clinical impact of high-throughput gene expression studies in lung cancer
Q38270567	Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons
Q26823978	Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges
Q27851527	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones
Q37581276	Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas
Q36519876	Clinical implications of genetic polymorphisms on stomach cancer drug therapy
Q34267563	Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
Q34488700	Clinical implications of the cancer genome
Q36565941	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
Q91596373	Clinical importance of long non‑coding RNA LINC00460 expression in EGFR‑mutant lung adenocarcinoma
Q27024235	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer
Q47548020	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
Q49930825	Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Q50629732	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.
Q54313342	Clinical next-generation sequencing in patients with non-small cell lung cancer.
Q31158651	Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations
Q54118554	Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung.
Q37750786	Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers
Q37334996	Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Q39457284	Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District.
Q36715107	Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Q43272211	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Q38019974	Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Q34029615	Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
Q37873453	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Q36316009	Clinical potential of gene mutations in lung cancer
Q36212891	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.
Q36345960	Clinical relevance of ion channels for diagnosis and therapy of cancer
Q34500155	Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
Q33873653	Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
Q34041761	Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation
Q47118266	Clinical significance of cripto-1 expression in lung adenocarcinoma
Q34582813	Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
Q42745155	Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib
Q46351405	Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer
Q90403153	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
Q84584265	Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib
Q38041563	Clinical testing for molecular targets for personalized treatment in lung cancer.
Q31128049	Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping
Q37196395	Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis
Q24630466	Clinical use of crizotinib for the treatment of non-small cell lung cancer
Q47704888	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
Q35180028	Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
Q92025240	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours
Q34011705	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
Q35107524	Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
Q33633606	Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma
Q37539427	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Q38077041	Clinically relevant cancer biomarkers and pharmacogenetic assays
Q80100938	Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma
Q37693426	Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation
Q35790161	Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis
Q35007886	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
Q54980290	Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression.
Q90217220	Clinicopathological and Prognostic Significance of EML4-ALK Rearrangement in Patients with Surgically Resected Lung Adenocarcinoma: A Propensity Score Matching Study
Q31167585	Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis
Q33633715	Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation
Q50738801	Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
Q54269790	Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.
Q34169194	Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer
Q64234032	Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with -positive non-small cell lung cancer
Q83568242	Clinicopathological features of lung adenocarcinoma with KRAS mutations
Q55259571	Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
Q51607504	Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas.
Q38784576	Clinicopathological significance of p14ARF expression in lung cancer: a meta-analysis
Q27027655	Clonal evolution in hematological malignancies and therapeutic implications
Q91272209	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers
Q34254343	Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas
Q40343596	Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Q45210729	Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).
Q92578527	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Q42200131	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Q33682941	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
Q34658204	Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Q36671123	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
Q33206782	Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer
Q27691448	Collaborative Care in NSCLC; the Role of Early Palliative Care
Q27853014	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab
Q37679938	Colorectal cancer in review: the role of the EGFR pathway
Q26824877	Combating acquired resistance to tyrosine kinase inhibitors in lung cancer
Q38812090	Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction
Q52588501	Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Q35043675	Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis
Q53681935	Combination of Pyrosequencing® and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR.
Q64111464	Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma
Q48352757	Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Q34318204	Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer
Q36795322	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma
Q38245873	Combination of stereotactic ablative body radiation with targeted therapies
Q92530282	Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
Q39118597	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer
Q33658626	Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Q36143394	Combinatorial biomarkers: From early toxicology assays to patient population profiling
Q24632064	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Q39009280	Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells
Q41811594	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
Q39310312	Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
Q35836350	Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
Q39051337	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Q34345154	Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma
Q37111832	Combined anti-proliferative and anti-angiogenic strategies for cancer
Q37080964	Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
Q54977986	Combined caveolin-1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer.
Q33881706	Combined effects of asbestos and cigarette smoke on the development of lung adenocarcinoma: different carcinogens may cause different genomic changes
Q57736167	Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
Q36230865	Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line
Q37522017	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
Q40167169	Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy
Q39559565	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway
Q39850353	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
Q91816037	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
Q34104025	Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
Q34206363	Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma
Q41635081	Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers
Q41892153	Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.
Q34066159	Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations
Q57279749	Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma
Q26852202	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC
Q38868047	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Q50056486	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Q38335360	Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors
Q57274907	Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes
Q34906960	Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.
Q35041632	Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin
Q42346456	Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers
Q92662253	Comparative Analysis of Two Methods for the Detection of EGFR Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients
Q60046465	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells
Q45770152	Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
Q24541311	Comparative analysis of cancer genes in the human and chimpanzee genomes
Q51667874	Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Q44219909	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer
Q33927591	Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
Q36519015	Comparative and integrative functional genomics of HCC.
Q36358798	Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.
Q35790108	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues
Q34560075	Comparing antibody and small-molecule therapies for cancer
Q60922980	Comparison of Clinicopathological Features and Prognosis between Rearrangements and Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
Q36660393	Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase In
Q36882732	Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Q89666748	Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer
Q36148697	Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer
Q34947842	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan
Q34756451	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
Q40368173	Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations
Q49593937	Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma.
Q85776063	Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
Q47162466	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Q36474664	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
Q41709088	Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis
Q54300832	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
Q46195110	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
Q30438089	Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer
Q89585374	Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients
Q37708814	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
Q54652248	Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.
Q54117313	Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
Q37644815	Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer
Q94453279	Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups
Q54941379	Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations.
Q38091669	Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Q37204325	Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation
Q40344659	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors
Q35541933	Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation.
Q40891431	Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma.
Q36865316	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS
Q39378163	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.
Q39477372	Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis.
Q33723528	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report
Q42920934	Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer
Q34359601	Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications.
Q93051199	Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
Q36491122	Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Q94564084	Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies
Q35712214	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
Q92968477	Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients
Q64075323	Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients
Q28606437	Comprehensive assessment of cancer missense mutation clustering in protein structures
Q36608839	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
Q30235944	Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
Q28274701	Comprehensive genomic characterization of squamous cell lung cancers
Q36544077	Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
Q39449489	Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer
Q42587971	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine
Q37580410	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology
Q37671783	Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers
Q39293400	Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma
Q30581942	Computational delineation of tyrosyl-substrate recognition and catalytic landscapes by the epidermal growth factor receptor tyrosine kinase domain
Q30374663	Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Q90541036	Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Q47308660	Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas
Q43059180	Con: the case for expanded lung cancer research support
Q36418752	Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers
Q99582766	Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Q37175551	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy
Q64092527	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Q36151764	Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma
Q36546095	Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study
Q90074730	Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents
Q50036265	Considerations About the Use of Biomarkers in Cancer Clinical Trials.
Q64256027	Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma
Q35832237	Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants
Q37707704	Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Q47107157	Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations
Q40670339	Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.
Q96126112	Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer
Q28547357	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
Q52983736	Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
Q37109227	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Q35605425	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
Q64098514	Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma
Q35772768	Cooperative Hedgehog-EGFR signaling
Q34489386	Cooperative, nanoparticle-enabled thermal therapy of breast cancer
Q36486421	Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
Q33704537	Correlation between (18)f-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in advanced lung cancer
Q33857652	Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer
Q39652063	Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy
Q47935277	Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China
Q34732930	Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma.
Q46171346	Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Q64252788	Correlation of Thyroid Transcription Factor-1 Expression with Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis
Q39669033	Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma
Q54477690	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
Q33792597	Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
Q36207143	Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.
Q92408657	Correlations Study Between 18F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma
Q33290653	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
Q36389901	Correlative studies in neuro-oncology trials: should they influence treatment?
Q40575534	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
Q90198180	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Q34410131	Coupled mutation finder: a new entropy-based method quantifying phylogenetic noise for the detection of compensatory mutations
Q38766833	Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
Q48510829	Creating incentives for genomic research to improve targeting of therapies.
Q36405628	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology
Q26738381	Crizotinib resistance: implications for therapeutic strategies
Q53148505	Crizotinib-induced toxicity in an experimental rat model.
Q37982440	Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer
Q35596686	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
Q33703063	Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma
Q37335142	Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer
Q36429474	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations
Q37314768	Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice
Q36365503	Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition
Q90056608	Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
Q34000044	Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy
Q26774502	Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
Q40076524	Current Japanese regulatory situations of pharmacogenomics in drug administration
Q46034707	Current Landscape of Targeted Therapy in Lung Cancer.
Q88566793	Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology
Q64890663	Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling.
Q39016850	Current Trends in Multidrug Optimization
Q38543780	Current and future molecular diagnostics in non-small-cell lung cancer.
Q37184167	Current aspects of targeted therapy in head and neck tumors
Q37723328	Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents
Q38172914	Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer
Q34310062	Current concepts on the molecular pathology of non-small cell lung carcinoma
Q35583920	Current management of gallbladder carcinoma
Q52715754	Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.
Q36849663	Current practices and guidelines for clinical next-generation sequencing oncology testing
Q36832121	Current role of antibody therapy in patients with metastatic colorectal cancer.
Q36452704	Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer
Q36364973	Current status of cetuximab for the treatment of patients with solid tumors.
Q35667739	Current status of immunotherapy for the treatment of lung cancer.
Q39298725	Current status of research and treatment for non-small cell lung cancer in never-smoking females
Q37790985	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Q43196880	Current tumor pathology. Clinical expectations of pathological diagnosis
Q34276419	Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.
Q33438894	Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
Q35146940	Customizing systemic therapy in patients with advanced non-small cell lung cancer
Q37043766	Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review
Q34684234	Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer
Q33932736	Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review
Q34637939	Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme
Q24303022	Cytohesins are cytoplasmic ErbB receptor activators
Q52031018	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival.
Q39673657	Cytokines and Growth Factors Stimulate Hyaluronan Production: Role of Hyaluronan in Epithelial to Mesenchymal-Like Transition in Non-Small Cell Lung Cancer
Q37890996	Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases
Q80142942	Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma
Q91756360	Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
Q54356882	Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Q50920187	Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.
Q38768617	Cytotoxicity of Salvia miltiorrhiza Against Multidrug-Resistant Cancer Cells.
Q55028849	Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Q36099324	DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients
Q35364690	DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations
Q37572189	DDX59 promotes DNA replication in lung adenocarcinoma
Q36471888	DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Q53725947	DNA Mutations May Not Be the Cause of Cancer.
Q35238487	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers
Q42755164	DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma
Q35892040	DNA-microarray analysis of brain cancer: molecular classification for therapy
Q35047411	DOK2 inhibits EGFR-mutated lung adenocarcinoma
Q54981550	Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Q45219658	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Q26778318	Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Q38273671	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Q47257690	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Q42355259	Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer
Q46228962	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
Q93545733	De la recherche de pointe au patient : un aller-retour?
Q38651333	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.
Q38609992	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States.
Q37285973	Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.
Q44660604	Decreased survival in EGFR gene amplified vulvar carcinoma
Q40135901	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.
Q33671802	Defining the blueprint of the cancer genome
Q37834359	Defining the cancer master switch
Q42707531	Defining the pathogenicity of DNA sequence variation
Q35631635	Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.
Q36088163	Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells
Q47314182	Deguelin induces PUMA-mediated apoptosis and promotes sensitivity of lung cancer cells (LCCs) to doxorubicin (Dox).
Q33779169	Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis
Q43518666	Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting
Q58408122	DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma
Q58697688	Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
Q36690711	Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry
Q89867948	Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death
Q64059776	Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC
Q33588217	Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging
Q54642118	Design and generation of MLPA probe sets for combined copy number and small-mutation analysis of human genes: EGFR as an example.
Q33936934	Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling
Q47623485	Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
Q35132338	Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers
Q82215956	Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making
Q91286819	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Q99350140	Destabilizing single chain major histocompatibility complex class I protein for repurposed enterokinase proteolysis
Q34092187	Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples
Q58695640	Detecting EGFR mutations in patients with non-small cell lung cancer
Q34589493	Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.
Q36866974	Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer
Q43246506	Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
Q37313331	Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples
Q35038358	Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing
Q38398139	Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
Q33582524	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
Q34467915	Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
Q36787803	Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
Q44509483	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations
Q37141952	Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping
Q47879384	Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma.
Q37709234	Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer
Q36755219	Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma
Q35787132	Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction
Q36278010	Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer
Q39437297	Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction
Q36835257	Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients.
Q47093966	Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
Q42907464	Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography
Q39531710	Detection of low-level EGFR T790M mutation in lung cancer tissues
Q35789640	Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.
Q29615033	Detection of mutations in EGFR in circulating lung-cancer cells
Q40251398	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors
Q36138364	Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma
Q46609599	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas
Q36497457	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood
Q33525226	Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
Q37146779	Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies
Q36085452	Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
Q34799198	Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood.
Q39129178	Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).
Q54272422	Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.
Q97567723	Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand
Q91344944	Development and validation of a targeted gene sequencing panel for application to disparate cancers
Q35612289	Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms
Q35968389	Development of TGF-beta signalling inhibitors for cancer therapy
Q39319196	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Q38717500	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Q50246515	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Q49802373	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.
Q37630493	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
Q34393558	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
Q38792120	Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
Q38793056	Development of indication criteria for preoperative examination in lung cancer
Q37833005	Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities
Q38956309	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond.
Q38930336	Diagnosis and Molecular Classification of Lung Cancer
Q33737293	Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer
Q46624082	Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
Q35244225	Diagnostic value of mutation-specific antibodies for immunohistochemical detection of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis
Q52903547	Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas.
Q37324081	Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis.
Q49166137	Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
Q47118230	Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma
Q37177513	Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
Q37269571	Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
Q52145217	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Q40016506	Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
Q39277085	Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer
Q35434274	Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors
Q90427149	Differential Gene Expression in Erlotinib-Treated Fibroblasts
Q58772425	Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
Q90411020	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Q41930710	Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes
Q40384212	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
Q36121683	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors
Q45848152	Differential expression and activation of epidermal growth factor receptor 1 (EGFR1), ERK, AKT, STAT3, and TWIST1 in nonsmall cell lung cancer (NSCLC).
Q33733522	Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status
Q41213157	Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma.
Q39032624	Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations
Q37708836	Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
Q39430288	Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
Q43200792	Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.
Q35967385	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
Q90193852	Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
Q47208190	Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status.
Q42131816	Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
Q64120213	Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma
Q36855852	Direct interaction of avermectin with epidermal growth factor receptor mediates the penetration resistance in Drosophila larvae
Q42652187	Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer
Q39478075	Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.
Q38202550	Discoidin domain receptors: a proteomic portrait
Q36847104	Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
Q50050248	Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 non-small cell lung cancer.
Q38605171	Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.
Q34152841	Discovering tumor suppressor genes through genome-wide copy number analysis
Q64075678	Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
Q39781895	Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors
Q30664020	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value
Q33566948	Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
Q93083358	Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy
Q38829629	Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells
Q38702793	Discovery of a potent dual ALK and EGFR T790M inhibitor
Q34701319	Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation
Q99584571	Discrete dynamic network modeling of oncogenic signaling: Mechanistic insights for personalized treatment of cancer
Q37421181	Disease diversity and FLT3 mutations
Q44331655	Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer
Q96950911	Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma
Q37078736	Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
Q60933000	Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
Q36547770	Dissecting cancer pathways and vulnerabilities with RNAi
Q27851628	Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
Q37285302	Distinct biological roles for the notch ligands Jagged-1 and Jagged-2.
Q28537922	Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders
Q36427883	Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells
Q42484909	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
Q46456054	Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma.
Q37328516	Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
Q51214174	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas.
Q37314999	Divide and conquer: progress in the molecular stratification of cancer
Q53792939	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics.
Q55387219	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
Q42145859	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Q39205689	Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Q35200480	Does the order of factors affect the product? Lessons learned from the TORCH trial
Q51576856	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer.
Q37709570	Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Q28237711	Double-stranded DNA in exosomes: a novel biomarker in cancer detection
Q53556638	Down Expression of FBP1 Is a Negative Prognostic Factor for Non-Small-Cell Lung Cancer.
Q53622918	Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Q24307767	Downregulation and growth inhibitory role of FHL1 in lung cancer
Q39510460	Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling
Q35227386	Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo
Q39048792	Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer
Q36498413	Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer
Q37815607	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
Q36179400	Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas
Q59080774	Drivers and passengers
Q48263037	Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA.
Q37282274	Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
Q37174391	Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
Q37634419	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma
Q36834883	Drug Resistance to EGFR Inhibitors in Lung Cancer
Q39390532	Drug Sensitivity Assays of Human Cancer Organoid Cultures
Q35827606	Drug development in oncology: classical cytotoxics and molecularly targeted agents
Q37970537	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Q39493552	Drug efficacy testing in mice
Q36893554	Drug insight: advances in renal cell carcinoma and the role of targeted therapies
Q36040613	Drug resistance and its significance for treatment decisions in non-small-cell lung cancer
Q37008882	Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents
Q94317317	Drug resistance in lung cancer
Q28537830	Drug resistance missense mutations in cancer are subject to evolutionary constraints
Q36801208	Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer
Q45327788	Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics
Q38664437	Drug-diagnostic co-development: challenges and issues
Q36735178	Drug-sensitive FGFR2 mutations in endometrial carcinoma
Q33564782	Drug-sensitive FGFR3 mutations in lung adenocarcinoma
Q28079559	Drugging the addict: non-oncogene addiction as a target for cancer therapy
Q28254233	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics
Q33860674	Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells
Q36258125	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Q34122718	Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Q37520544	Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D.
Q39091696	Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation
Q37382669	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
Q33759715	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Q37363050	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
Q36273532	Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
Q37126666	DxS Ltd.
Q41694055	Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment.
Q24294659	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA)
Q42362771	Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
Q36670951	Dynamics of biological systems: role of systems biology in medical research
Q36746250	Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
Q55334265	Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
Q44323391	EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma
Q37438426	EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
Q38951627	EGF potentiation of VEGF production is cell density dependent in H292 EGFR wild type NSCLC cell line
Q24561953	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
Q37799824	EGF receptor in lung cancer: a successful story of targeted therapy
Q38034817	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity
Q29619032	EGF-ERBB signalling: towards the systems level
Q40235641	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
Q37043503	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
Q57032248	EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
Q36044399	EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
Q36971209	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer
Q37240726	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
Q36244968	EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
Q30397503	EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib
Q35606916	EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Q49959764	EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Q93183634	EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil
Q36687288	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Q33859707	EGFR Mutations in Latinos From the United States and Latin America.
Q91637156	EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis
Q46411995	EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer
Q34627605	EGFR Signaling in Colorectal Carcinoma
Q35040888	EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation
Q47836622	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
Q42701535	EGFR T790M: revealing the secrets of a gatekeeper
Q45886897	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Q39167752	EGFR TKI combination with immunotherapy in non-small cell lung cancer
Q99728118	EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
Q36048238	EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
Q36733618	EGFR and HER2 signaling in breast cancer brain metastasis
Q54495025	EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Q41829016	EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy
Q34346624	EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition
Q36419182	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
Q37790671	EGFR and KRAS in colorectal cancer
Q34096414	EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.
Q47780922	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
Q38391135	EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study
Q53238557	EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Q37205334	EGFR and KRAS mutations in patients with adenocarcinoma of the lung
Q38160089	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
Q80647736	EGFR and gastrointestinal stromal tumor: an immunohistochemical and FISH study of 82 cases
Q46039810	EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.
Q33576802	EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Q37021792	EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Q33963199	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Q62127975	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
Q33372792	EGFR expression in gallbladder carcinoma in North America
Q46513909	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
Q27851658	EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
Q53249127	EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma.
Q40378678	EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization
Q38796569	EGFR gene mutation in gastrointestinal stromal tumours.
Q44690866	EGFR gene mutations in patients with adenosquamous lung carcinoma.
Q48014727	EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Q37180302	EGFR inhibition in non-small cell lung cancer: current evidence and future directions
Q24794815	EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head
Q38257898	EGFR inhibitors and autophagy in cancer treatment
Q38120309	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.
Q43849261	EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Q37767383	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
Q36306259	EGFR inhibitors: what have we learned from the treatment of lung cancer?
Q34008570	EGFR isoforms and gene regulation in human endometrial cancer cells
Q36772144	EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.
Q36758325	EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy
Q37709182	EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Q38554153	EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma
Q37191983	EGFR lung cancer mutants get specialized
Q46717312	EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.
Q41065727	EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer
Q53538486	EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Q46055656	EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics
Q46853023	EGFR mutation in gefitinib-responsive small-cell lung cancer
Q46484941	EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report.
Q35164306	EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry
Q80100696	EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer
Q34992513	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
Q58793364	EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
Q38053963	EGFR mutation status in brain metastases of non-small cell lung carcinoma.
Q36611944	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
Q64109081	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer
Q38061599	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
Q45243918	EGFR mutation testing practice in advanced non-small cell lung cancer
Q38379393	EGFR mutation testing using archival-stained smears in non-small cell lung carcinoma.
Q36135844	EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy
Q30664830	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
Q46236872	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
Q98938383	EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell cancer in South India
Q83093506	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer
Q37434212	EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
Q46263820	EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas
Q26852507	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
Q43238274	EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features
Q34688967	EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy
Q54112709	EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China.
Q36579633	EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
Q38515822	EGFR mutations in lung cancer: from tissue testing to liquid biopsy
Q35800614	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Q37566609	EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
Q34167004	EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis
Q37421036	EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
Q54117532	EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
Q55502873	EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication.
Q51794333	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.
Q36348040	EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
Q46653404	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women
Q51744466	EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma.
Q46054209	EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan
Q38171032	EGFR signaling and autophagy dependence for growth, survival, and therapy resistance
Q46677125	EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids
Q38552978	EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection
Q24652337	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Q34618994	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma
Q36557678	EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
Q28243483	EGFR testing in lung cancer is ready for prime time
Q37177600	EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
Q46837947	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients
Q37393940	EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Q38089244	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
Q38106905	EGFR tyrosine kinase inhibitors: difference in efficacy and resistance
Q39362508	EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
Q39538057	EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride
Q42731684	EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma
Q37561771	EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?
Q36741251	EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
Q35893808	EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence
Q36947038	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment
Q33727426	EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
Q38807586	EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma
Q90224747	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
Q36285611	EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
Q40562646	EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Q53698558	EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
Q30871237	EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Q57485837	EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?
Q37538757	EGFR-directed therapies to treat non-small-cell lung cancer
Q24335999	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance
Q60449321	EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome
Q24606177	EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib
Q34406334	EGFR-mutated lung cancer: a paradigm of molecular oncology
Q37160173	EGFR-targeted therapies in lung cancer: predictors of response and toxicity
Q36619212	EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation
Q37682778	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
Q36826056	EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
Q37206247	EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Q46640557	EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients
Q35619241	EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Q80100754	EGFR: a prognostic and/or a predictive marker?
Q35078031	EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression
Q55457200	EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Q34356008	EGFs and ERBBs--brief history and prospects
Q35730962	EML4-ALK fusion gene in Korean non-small cell lung cancer
Q46113744	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Q24645724	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
Q36335816	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer
Q54727452	EML4-ALK: honing in on a new target in non-small-cell lung cancer.
Q39220097	EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway
Q37589341	EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.
Q38805633	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
Q35532215	EPMA position paper in cancer: current overview and future perspectives
Q36355962	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma
Q29619520	ERBB receptors and cancer: the complexity of targeted inhibitors
Q33601653	ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics
Q90101145	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Q38919117	ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas
Q37337542	ERBBs in the gastrointestinal tract: recent progress and new perspectives
Q85303113	ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer
Q99419149	EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
Q52649612	ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.
Q37661108	ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition
Q28741454	EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas
Q33392707	Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Q33947163	Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells
Q54113607	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations.
Q35571704	Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
Q36439557	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma
Q26747510	Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability
Q58545847	Effect Sizes of Somatic Mutations in Cancer
Q64109900	Effect of Cetuximab and Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type and Use of as a Possible Biomarker for Treatment Responsiveness
Q64072904	Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients
Q79782947	Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients
Q53519220	Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
Q40337329	Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
Q36524729	Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
Q37090804	Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice
Q92298178	Effect of miR-140-5p on the regulation of proliferation and apoptosis in NSCLC and its underlying mechanism
Q35221485	Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.
Q35699603	Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
Q38634910	Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis
Q54973430	Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
Q54979668	Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.
Q34041701	Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Q38956327	Effectiveness of maintenance treatments for nonsmall cell lung cancer
Q36036046	Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines
Q37389605	Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis
Q37000538	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
Q54356532	Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Q36733598	Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
Q36967631	Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase
Q89092109	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Q36631504	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
Q36924484	Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
Q54210501	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
Q54347207	Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
Q34050239	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Q36247866	Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma
Q46008308	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Q36616462	Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines
Q41099007	Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study
Q52893820	Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
Q35233470	Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
Q36351290	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.
Q33485003	Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study
Q34785940	Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma
Q51296848	Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Q36438421	Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening
Q36116287	Electrical detection of cancer biomarker using aptamers with nanogap break-junctions
Q92134578	Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients
Q35064133	Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells
Q39971699	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Q39828170	Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.
Q37099888	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer
Q39473591	Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients
Q43261058	Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
Q35948915	Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs
Q79886528	Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib
Q37691441	Emerging MEK inhibitors.
Q37588717	Emerging Raf inhibitors.
Q98944239	Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer
Q38623361	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Q36758593	Emerging drugs for mesothelioma
Q36944022	Emerging drugs for targeted therapy of bladder cancer.
Q35914897	Emerging insights into the molecular and cellular basis of glioblastoma
Q37848663	Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer
Q36084718	Emerging molecular classification in renal cell carcinoma: implications for drug development
Q38642455	Emerging molecular targets and therapy for cholangiocarcinoma
Q37269316	Emerging options for the management of non-small cell lung cancer
Q37249366	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
Q45216006	Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Q33892582	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Q28078928	Emerging roles of Nrf2 signal in non-small cell lung cancer
Q35988130	Emerging strategies and applications of pharmacogenomics
Q35008971	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape
Q28070165	Emerging therapeutic agents for lung cancer
Q37030800	Emerging therapies for malignant glioma
Q64089193	Emerging therapies for non-small cell lung cancer
Q34483953	Emerging treatment for advanced lung cancer with EGFR mutation
Q36228352	Emerging treatment options for patients with recurrent advanced thymic epithelial tumors
Q36519807	Emerging treatments for choroidal metastases
Q46071509	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Q39841334	Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation
Q42869980	Endocytosis and cancer
Q37549617	Endocytosis and signalling: a meeting with mathematics
Q38892107	Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells
Q37129376	Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
Q46424042	Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells
Q35051626	Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models
Q39124519	Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer
Q27305848	Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
Q36484536	Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
Q33648864	Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database
Q39363203	Epidemiological profile and prognostic factors in patients with lung cancer
Q36337982	Epidemiology informing clinical practice: from bills of mortality to population laboratories
Q90150760	Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran
Q47261688	Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Q36322658	Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Q92454757	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Q33803406	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
Q33737298	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Q47614764	Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide
Q58567008	Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation
Q36040002	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis
Q38460428	Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Q80393070	Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha
Q36239648	Epidermal growth factor inhibition in solid tumours
Q57692990	Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer
Q40212739	Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
Q33302191	Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.
Q36485352	Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Q35667627	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update
Q36458742	Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
Q39828582	Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer
Q28284519	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Q34781380	Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.
Q54361563	Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).
Q82500381	Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
Q30850656	Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Q39254692	Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.
Q44740671	Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy
Q47116265	Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
Q36014004	Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas
Q27865182	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Q42818168	Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations
Q33575439	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
Q35549063	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies
Q36907221	Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors
Q35956330	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
Q54494664	Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Q38995524	Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
Q37790320	Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
Q28080187	Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer
Q36653667	Epidermal growth factor receptor as a major anticancer drug target
Q34195184	Epidermal growth factor receptor copy number in potentially malignant oral disorders and oral squamous cell carcinoma: a short communication and preliminary study.
Q46679323	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors
Q40448827	Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.
Q36728450	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Q36503084	Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance
Q46371923	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Q40332214	Epidermal growth factor receptor expression and activation in neuroendocrine tumours
Q34411696	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
Q42052616	Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients
Q39335663	Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis
Q33691211	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
Q81414066	Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade
Q92134583	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
Q44485092	Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer
Q33942092	Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.
Q34557318	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
Q40756893	Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis
Q54538613	Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
Q80584656	Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung
Q57075013	Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro
Q44051250	Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma
Q35164907	Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region
Q37476827	Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
Q28084216	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
Q54416267	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.
Q35642677	Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.
Q34105339	Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance
Q28088636	Epidermal growth factor receptor in non-small cell lung cancer
Q37132640	Epidermal growth factor receptor in pancreatic cancer.
Q37634598	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Q35013457	Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy
Q36504349	Epidermal growth factor receptor inhibition and non-small cell lung cancer
Q36071392	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy
Q28475894	Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy
Q36482542	Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer
Q36157284	Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer
Q36429442	Epidermal growth factor receptor inhibitors in cancer treatment.
Q34382797	Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?
Q36830108	Epidermal growth factor receptor inhibitors in non-small cell lung cancer
Q38088756	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer
Q36302860	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer
Q35222011	Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells
Q43555541	Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
Q37123445	Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas
Q37252270	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
Q35812818	Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients
Q37719929	Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review
Q37265114	Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables
Q33824203	Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
Q37102688	Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
Q34676580	Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung
Q50096967	Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma.
Q44669701	Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients
Q45272652	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma
Q54569001	Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?
Q54395887	Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
Q33617464	Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
Q34575299	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer
Q37232048	Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung
Q51491538	Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors.
Q84409820	Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors
Q58082495	Epidermal growth factor receptor mutations in Chinese patients with laryngeal squamous cell carcinoma
Q54179471	Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients.
Q38174770	Epidermal growth factor receptor mutations in lung adenocarcinoma
Q29615474	Epidermal growth factor receptor mutations in lung cancer
Q36817294	Epidermal growth factor receptor mutations in lung cancers.
Q39918647	Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling
Q36662504	Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait
Q53270990	Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area.
Q36429519	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer
Q40190070	Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma
Q53564370	Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Q33996096	Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib
Q43407740	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma
Q39739616	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells
Q39752055	Epidermal growth factor receptor signaling in nonsmall cell lung cancer
Q34561698	Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway
Q38207484	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors
Q49468021	Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Q36014238	Epidermal growth factor receptor status in anaplastic thyroid carcinoma
Q33315034	Epidermal growth factor receptor structural alterations in gastric cancer
Q34159125	Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Q39165055	Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia
Q36660669	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease
Q34031229	Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Q38763111	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future
Q24653036	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
Q37431620	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
Q38594474	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
Q35290807	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future
Q38701670	Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Q36402837	Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
Q38168795	Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
Q34589789	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
Q36493232	Epidermal growth factor receptor-targeted agents for lung cancer
Q40038133	Epidermal growth factor receptor-targeted therapy.
Q36119978	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma
Q38888532	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis
Q54329048	Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
Q90886378	Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Q33779882	Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized
Q36042698	Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Q36938216	Epigenetic Therapy in Lung Cancer - Role of microRNAs
Q38150749	Epistatic interactions and drug response
Q82917858	Epithelial growth factor receptor status in primary and recurrent ovarian cancer
Q24535592	Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Q37977436	Epithelial mesenchymal transition and lung cancer
Q36399326	Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"?
Q34095970	Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare.
Q38729111	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Q37668848	ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases
Q37970020	ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective
Q36545883	ErbB receptor negative regulatory mechanisms: implications in cancer
Q36677496	ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas
Q24683709	ErbB receptors: from oncogenes to targeted cancer therapies
Q33928631	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Q37249978	ErbBs in lung cancer
Q37419295	Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Q35263024	Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
Q40161836	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha
Q38245038	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Q38841850	Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.
Q33945734	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Q24685474	Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth
Q54616855	Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Q36425173	Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Q36224756	Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.
Q43955796	Erlotinib hydrochloride
Q34266864	Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Q36161290	Erlotinib in non-small cell lung cancer: a review
Q36968183	Erlotinib in non-small-cell lung cancer
Q48597941	Erlotinib in patients with advanced lung squamous cell carcinoma.
Q35628121	Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Q37307567	Erlotinib in the treatment of advanced pancreatic cancer
Q36284485	Erlotinib in the treatment of non-small cell lung cancer
Q37290401	Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
Q39975225	Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Q33275026	Erlotinib inhibits growth of a patient-derived chordoma xenograft
Q35558557	Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
Q36228534	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
Q36151475	Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study
Q39121775	Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Q42017054	Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Q34134464	Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Q35996048	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials
Q34657690	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Q46542092	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Q27851712	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Q35152542	Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo
Q37754925	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Q36839754	Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer
Q38970911	Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib
Q38694441	Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Q36834539	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient.
Q35921330	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
Q37028611	Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies
Q41672200	Estimation of age-related DNA degradation from formalin-fixed and paraffin-embedded tissue according to the extraction methods
Q35051314	Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
Q38434138	Estrogen receptor signaling pathways in human non-small cell lung cancer
Q33561588	Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme
Q34657570	Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer
Q41171803	Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology
Q37399540	Ethnic differences and functional analysis of MET mutations in lung cancer
Q35943089	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
Q61455095	Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer
Q47099044	Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer
Q37432535	Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.
Q38753542	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Q53306420	Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.
Q38686009	Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status
Q51319681	Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Q41973777	Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
Q79346134	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer
Q33379967	Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
Q36611204	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Q36966128	Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Q40977709	Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
Q51700829	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Q36523502	Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients
Q41994944	Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement
Q39716869	Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
Q37883964	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer
Q36582547	Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma
Q43846394	Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.
Q39308716	Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis
Q50674470	Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma.
Q38844092	Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Q91729686	Evolution of Small Molecule Kinase Drugs
Q47816379	Evolution of early phase clinical trials in oncology
Q58613175	Evolution of platinum resistance in high-grade serous ovarian cancer
Q33557413	Evolution of systemic therapy for advanced pancreatic cancer
Q35591358	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer
Q36327195	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
Q40228498	Evolving '-omics' technologies in the drug development process.
Q30398030	Evolving health care through personal genomics
Q34529131	Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Q37349280	Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
Q83106750	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
Q37255147	Existing and emerging technologies for tumor genomic profiling
Q28743468	Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines
Q37416668	Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease.
Q35669012	Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer
Q33621754	Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck
Q43195723	Expanding options for EGFR targeting in lung cancer
Q34359274	Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib
Q38524526	Experience with erlotinib in the treatment of non-small cell lung cancer
Q26799390	Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
Q39288360	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.
Q29615120	Exploiting the PI3K/AKT pathway for cancer drug discovery
Q58802587	Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
Q37818230	Exploration of synthetic lethal interactions as cancer drug targets
Q41920903	Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patients
Q54319566	Exploring microRNA-mediated alteration of EGFR signaling pathway in non-small cell lung cancer using an mRNA:miRNA regression model supported by target prediction databases.
Q52688847	Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
Q83855416	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma
Q36341754	Expression biomarkers for clinical efficacy and outcome prediction in cancer
Q39144184	Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes
Q35218145	Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer
Q36774633	Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
Q38329982	Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
Q36010179	Expression of EGFR Is Closely Related to Reduced 3-Year Survival Rate in Chinese Female NSCLC
Q34745805	Expression of NRG1 and its receptors in human bladder cancer
Q40117486	Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling
Q35238466	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380
Q80587761	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma
Q35036471	Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations
Q37457741	Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma
Q30009050	Expression pattern of FGFR2, Grb2 and Plcγ1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma
Q38296583	Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification
Q37291399	FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid
Q91982178	FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Q42059865	FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators
Q24296333	FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice
Q35073348	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma
Q47307357	FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Q53089675	FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Q38234978	FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
Q39297937	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Q38966912	FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
Q36406190	FGFR1 amplification in squamous cell carcinoma of the lung
Q47260594	FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.
Q36251184	FLT3 tyrosine kinase inhibitors
Q40371743	FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Q61813957	FOSB⁻PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer
Q35745004	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
Q39281214	Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
Q28252845	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Q39809931	Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition
Q35073353	Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies
Q43101561	Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor
Q36439363	Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.
Q54977963	Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations.
Q37427038	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
Q55363718	Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.
Q41729710	Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain.
Q37831109	Feedback regulation of EGFR signalling: decision making by early and delayed loops.
Q64931081	Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer.
Q24658237	Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells
Q90616691	Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer
Q36924414	Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met
Q37639588	Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
Q60918185	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Q54246031	Finding the missing links in EGFR.
Q93382354	Fine-needle aspiration cytology of non-small cell lung carcinoma: A paradigm shift
Q60921601	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?
Q48004901	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC).
Q41569372	First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies
Q34386915	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Q43639934	First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Q47763039	First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Q38088215	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments
Q37625444	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
Q38221293	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.
Q38032437	First-line therapy of mutated non-small cell lung cancer: an update
Q54186267	First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
Q36283596	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Q64228070	First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
Q34591159	Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer
Q37164590	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Q50876305	Flavonoids and Tannins from Smilax china L. Rhizome Induce Apoptosis Via Mitochondrial Pathway and MDM2-p53 Signaling in Human Lung Adenocarcinoma Cells.
Q39284284	Flexible lab-tailored cut-offs for suitability of formalin-fixed tumor samples for diagnostic mutational analyses
Q55030214	Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Q41965926	Fluorescent signatures for variable DNA sequences
Q36939898	Flying under the radar: the new wave of BCR-ABL inhibitors
Q28550689	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
Q38089600	Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
Q35845580	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice
Q42368437	Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation
Q35200424	Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy
Q34669260	Fool's gold, lost treasures, and the randomized clinical trial
Q39528185	Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
Q83230378	Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4
Q37698293	Four-dimensional dynamics of MAPK information processing systems.
Q40929491	Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study
Q92798844	Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
Q27851448	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
Q34673282	Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer
Q35915133	Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
Q37110396	Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?
Q35016912	Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity
Q35871742	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis
Q46607446	Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung
Q54284515	Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Q27851615	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Q38489488	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Q46738962	Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
Q80173694	From bench to bedside and back again?
Q28533949	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development
Q50123361	From biology to therapy: Improvements of therapeutic options in Lung cancer.
Q24621007	From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway
Q92302884	From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science
Q37551148	From drug discovery to biomarker-driven clinical trials in lymphoma
Q37003218	From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Q26830811	From modules to medicine: How modular domains and their associated networks can enable personalized medicine
Q55093479	From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo.
Q46560311	From nihilism to individualism: the evolution of lung cancer therapy
Q37236447	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics
Q28385559	From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience
Q35117568	From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer
Q26864637	From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience
Q90612116	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Q34094224	Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
Q93337424	Fully automated real-time PCR for EGFR testing in non-small cell lung carcinoma
Q36120023	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
Q37732019	Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer
Q36221780	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Q51739953	Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.
Q33838325	Functional characterization of human cancer-derived TRKB mutations
Q34423170	Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach
Q54977360	Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Q33368629	Functional copy-number alterations in cancer
Q37999073	Functional drug-gene interactions in lung cancer.
Q45933675	Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
Q85001306	Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma
Q48013156	Functional precision cancer medicine-moving beyond pure genomics
Q37269270	Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC
Q36895812	Future of molecular profiling of human hepatocellular carcinoma
Q35404376	Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial
Q42702662	GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers.
Q49789981	GRK5 functions as an oncogenic factor in non-small-cell lung cancer.
Q61804215	GSK-3β regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models
Q55070732	Gain of copy number and amplification of the RET gene in lung cancer.
Q35067654	Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma
Q40161268	Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib
Q34768400	Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells
Q54719163	Gastrointestinal toxicities of novel agents in cancer therapy.
Q33265628	Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
Q39400141	Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells
Q36135604	Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Q64969430	Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer.
Q28485309	Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa
Q54564062	Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Q35345489	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Q36740873	Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
Q46333966	Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Q36612517	Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
Q37929795	Gefitinib for non-small-cell lung cancer treatment
Q88123698	Gefitinib for oesophageal cancer: a cog in need of a wheel?
Q37357287	Gefitinib for the treatment of non-small-cell lung cancer
Q37738913	Gefitinib for the treatment of non-small-cell lung cancer.
Q36512046	Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)
Q35031807	Gefitinib in non small cell lung cancer
Q36161284	Gefitinib in non-small cell lung cancer
Q36610166	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Q37449013	Gefitinib in the treatment of advanced non-small-cell lung cancer
Q26739096	Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
Q54321696	Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Q28534577	Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification
Q36155335	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients
Q50506376	Gefitinib plus Fuzheng Kang'ai Formula () in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial.
Q29620605	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Q36065216	Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity
Q34114278	Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Q33231452	Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation
Q36615832	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
Q53513542	Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Q44679030	Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study
Q29619975	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Q46232500	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Q30544631	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Q42328764	Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations
Q37419104	Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer
Q45169148	Gefitinib--a novel targeted approach to treating cancer
Q28469345	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
Q35580846	Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells
Q36661222	Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines
Q43042819	Gefitinib: a consideration of cost
Q38338492	Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Q33207883	Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer
Q33915997	Gemcitabine for the treatment of advanced nonsmall cell lung cancer
Q64238805	Gene Expression Profiling Reveals Distinct Molecular Subtypes of Esophageal Squamous Cell Carcinoma in Asian Populations
Q37221902	Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations
Q94603193	Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker
Q36755676	Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
Q83139511	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
Q46465639	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Q41714879	Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method
Q38378815	Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients
Q33263277	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
Q40141195	Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma
Q39312152	Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Q24809183	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy
Q34994030	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer
Q39159155	Gene silencing of c-Met leads to brain metastasis inhibitory effects
Q28397345	Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies
Q34566773	Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis
Q33829488	Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
Q54114243	Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.
Q38198930	Genetic Interactions of STAT3 and Anticancer Drug Development
Q40498334	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors
Q35898597	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer
Q36695240	Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
Q36524569	Genetic alterations in lung adenocarcinoma with a micropapillary component
Q40040928	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines
Q36393012	Genetic alterations in urothelial bladder carcinoma: an updated review
Q34674319	Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer
Q34125003	Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance
Q33520794	Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Q36115735	Genetic changes in squamous cell lung cancer: a review
Q37899883	Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
Q35897344	Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
Q37977835	Genetic insight and therapeutic targets in squamous-cell lung cancer
Q34832117	Genetic modifiers of EGFR dependence in non-small cell lung cancer
Q37113682	Genetic predictors of MEK dependence in non-small cell lung cancer
Q34658903	Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer
Q33693846	Genetic-based prediction of disease traits: prediction is very difficult, especially about the future
Q37765099	Genetics of biliary tract cancers and emerging targeted therapies
Q36344243	Genetics of drug resistance
Q39872383	Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
Q28391355	Genome stability pathways in head and neck cancers
Q28385454	Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma
Q33598001	Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer
Q37037246	Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers
Q34354428	Genome-wide identification of significant aberrations in cancer genome.
Q82452891	Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway
Q37028708	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Q35671373	Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing
Q92555522	Genomic Medicine-Progress, Pitfalls, and Promise
Q55457466	Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations.
Q33313648	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
Q49678076	Genomic alterations of ERBB receptors in cancer: clinical implications.
Q37427132	Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor
Q35079683	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity
Q36195093	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer
Q35873554	Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer
Q34104493	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Q35036588	Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status
Q38060203	Genomic biomarkers for patient selection and stratification: the cancer paradigm.
Q36851245	Genomic landscape of non-small cell lung cancer in smokers and never-smokers
Q38231825	Genomic medicine and targeted therapy for solid tumors
Q38114005	Genomic medicine: a decade of successes, challenges, and opportunities
Q37269251	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
Q36207381	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
Q26853507	Genomic sequencing in cancer
Q35807322	Genomic technology applied to pharmacological traits
Q35252277	Genomics and drug response
Q36084693	Genomics of lung cancer may change diagnosis, prognosis and therapy
Q92830555	Genomics-Enabled Precision Medicine for Cancer
Q37376509	Genomics: applications in mechanism elucidation
Q35519172	Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy
Q35146927	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
Q27851633	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Q36660664	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies
Q33275318	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1
Q33901617	Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma
Q35546231	Germline EGFR T790M mutation found in multiple members of a familial cohort
Q40732783	Germline mutations causing familial lung cancer
Q33367793	Germline polymorphisms as modulators of cancer phenotypes
Q94481864	Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei
Q40116157	Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.
Q38460865	Glioblastoma: pathology, molecular mechanisms and markers
Q35089063	Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer
Q37699154	Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
Q30447539	Gold nanoparticles: From nanomedicine to nanosensing.
Q34059536	Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
Q27851566	Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Q90429716	Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
Q42035610	Grand challenge commentary: Informative diagnostics for personalized medicine.
Q46939852	Griffipavixanthone from Garcinia oblongifolia champ induces cell apoptosis in human non-small-cell lung cancer H520 cells in vitro
Q49287962	Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.
Q37045217	Growth factors and oncogenes as targets in melanoma: lost in translation?
Q34064620	Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein
Q37631021	Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.
Q39622232	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
Q90448494	HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
Q37073441	HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer
Q36734936	HER family inhibitors in pancreatic cancer: current status and future directions
Q33699007	HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
Q36217582	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme
Q36061145	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.
Q36322762	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
Q41308137	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer
Q55045037	HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
Q36615002	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
Q39263953	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
Q36822204	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
Q33586269	HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma
Q52717015	Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.
Q54257595	Harnessing massively parallel DNA sequencing for the personalization of cancer management.
Q37411128	Harnessing plasma genotyping for precision therapy against lung cancer
Q89634774	Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Q36249234	Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer
Q58197295	Head and neck cancer: from research to therapy and cure
Q35762499	Heat shock protein 90 inhibition in lung cancer
Q38819110	Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers
Q46268586	Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"
Q42995833	Heparin-binding EGF-like factor augments esophageal epithelial cell proliferation, migration and inhibits TRAIL-mediated apoptosis via EGFR/MAPK signaling.
Q38377273	Hepatocyte growth factor and Met in drug discovery
Q36842715	Her signaling in pancreatic cancer
Q33747967	Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system
Q92163099	Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
Q27853391	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
Q38065082	Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer
Q42227138	Heterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck - implication for gefitinib
Q30157152	Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations
Q36793862	High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.
Q53300836	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.
Q36051484	High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients
Q41708722	High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
Q38776722	High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival
Q28304785	High frequency of BRAF V600E mutations in ameloblastoma
Q46448637	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Q33717222	High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)
Q25257525	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization
Q33336861	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
Q33267389	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.
Q37619902	High sensitivity EndoV mutation scanning through real-time ligase proofreading
Q40822344	High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
Q87745890	High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer
Q28740553	High throughput interrogation of somatic mutations in high grade serous cancer of the ovary
Q37109744	High-content analysis of cancer genome DNA alterations
Q36477716	High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies
Q38754469	High-throughput Phenotyping of Lung Cancer Somatic Mutations
Q45901707	High-throughput biochemical kinase selectivity assays: panel development and screening applications.
Q34050186	High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
Q39991911	High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor
Q36288148	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Q36497083	High-throughput mutational analysis of the human cancer genome
Q57693480	High-throughput oncogene mutation profiling in human cancer
Q42316845	High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients
Q36591388	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Q40476723	Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.
Q27851714	Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer
Q37068513	Highly parallel identification of essential genes in cancer cells
Q50465588	Highly sensitive EGFR mutation detection by specific amplification of mutant alleles.
Q38164052	Histo-cytological diagnostic accuracy in lung cancer
Q48132127	Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
Q40109306	Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.
Q33904760	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma
Q48150376	Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Q37598057	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Q42292319	Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Q38858961	Honokiol targets mitochondria to halt cancer progression and metastasis
Q95260313	Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer
Q37793837	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Q37245907	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
Q37588365	How and when to use genetic markers for nonsmall cell lung cancer.
Q37065678	How genetically engineered mouse tumor models provide insights into human cancers
Q26992045	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Q48411592	How to develop novel treatments for EGFR-mutant lung cancer.
Q37587294	How to unleash mitochondrial apoptotic blockades to kill cancers?
Q36429550	How will lung cancer be treated in the future?
Q40352167	Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
Q36982771	Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines
Q27023576	Human correlates of provocative questions in pancreatic pathology
Q37538406	Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib
Q52655439	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
Q37379240	Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates
Q60050105	Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Q35591083	Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer
Q89206292	Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
Q40147314	Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway
Q39302684	Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Q38968478	Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Q38659248	ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection
Q35631086	IGDB.NSCLC: integrated genomic database of non-small cell lung cancer
Q39101764	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
Q35833023	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.
Q37520432	IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Q47773490	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Q38666574	Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
Q38352862	Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer
Q36843769	Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells
Q79448974	Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
Q38668707	Identification and Validation of Driver Kinases from Next-Generation Sequencing Data
Q36557174	Identification and characterization of RET fusions in advanced colorectal cancer
Q30877356	Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
Q24633776	Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
Q42646980	Identification of 10 Candidate Biomarkers Distinguishing Tuberculous and Malignant Pleural Fluid by Proteomic Methods.
Q34354515	Identification of 33 candidate oncogenes by screening for base-specific mutations.
Q98384563	Identification of 4-Anilino-6-aminoquinazoline Derivatives as Potential MERS-CoV Inhibitors
Q47100541	Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer
Q92350228	Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis
Q46393465	Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy
Q54268313	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Q92102263	Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters
Q91844098	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis
Q43161186	Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers
Q41637034	Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma
Q39167915	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo
Q51326919	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC.
Q34887667	Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity
Q61815055	Identification of antiproliferative emodin analogues as inhibitors of epidermal growth factor receptor in cancer
Q28239452	Identification of cancer genes by mutational profiling of tumor genomes
Q45030586	Identification of driver mutations in lung cancer: first step in personalized cancer
Q54457108	Identification of epidermal growth factor receptor (EGFR) exon 20 single nucleotide polymorphism in Chinese squamous cell carcinoma of head and neck (SCCHN).
Q37368954	Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma
Q31132212	Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining
Q41623567	Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway
Q37323468	Identification of molecular targets in urologic oncology
Q33690276	Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients
Q64105070	Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer
Q35166315	Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Q91793139	Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer
Q36897470	Identification of structural aberrations in cancer by SNP array analysis
Q46557776	Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck
Q28511622	Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification
Q27851410	Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Q36127636	Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
Q91742348	Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma
Q26781810	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer
Q34295696	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
Q90610221	Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks
Q35264584	Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
Q36328508	Identifying molecular markers for the early detection of pancreatic neoplasia
Q38420747	Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Q89926672	Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
Q37889967	Identifying responders to trastuzumab therapy in breast cancer
Q55401345	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants.
Q37187172	Imaging Characteristics in ALK Fusion-Positive Lung Adenocarcinomas by Using HRCT.
Q38137829	Imaging EGFR and HER2 by PET and SPECT: a review
Q38852701	Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective.
Q37320501	Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
Q36050371	Imaging of lung cancer in the era of molecular medicine
Q36654677	Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER
Q38206386	Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses
Q37898427	Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
Q38868664	Immunohistochemical analysis of EGFR and hyaluronan in tongue cancer and the development of regional recurrence in patients initially diagnosed N0.
Q54399363	Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Q34008820	Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis
Q34158993	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma
Q47140225	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Q51046274	Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
Q57069991	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
Q38367414	Immunotherapy for lung cancer: for whom the bell tolls?
Q51132444	Immunotherapy in lung cancer.
Q55312983	Immunotherapy in the Asiatic population: any differences from Caucasian population?
Q52624361	Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Q36797398	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Q26751473	Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Q47654457	Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.
Q39957730	Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro
Q34339890	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
Q38937520	Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.
Q50853655	Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Q34028470	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib
Q35852269	Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency.
Q36534696	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Q42949033	Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma
Q50321656	Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.
Q37471822	Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation
Q92646422	Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion
Q37742492	Impact of biomarkers on non-small cell lung cancer treatment
Q40876078	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
Q97538360	Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
Q41612456	Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians
Q42167271	Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma
Q24625201	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials
Q53597217	Impact of genetic diagnostics on drug development strategy.
Q80845931	Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer
Q89543321	Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
Q85515558	Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene
Q41879278	Impact of thymidylate synthase protein expression on efficacy of chemotherapy in advanced lung cancer patients
Q92334155	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer
Q35560129	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.
Q62512297	Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
Q37186795	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
Q39712642	Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations
Q39045171	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
Q34163458	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps
Q37005953	Implementation of genetics to personalize medicine
Q38320914	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan
Q36383418	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Q34404229	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts
Q37118974	Implications of EGFR PharmDx kit for cetuximab eligibility
Q26764917	Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
Q37678306	Implications of key trials in advanced nonsmall cell lung cancer
Q98386333	Implications of lipid droplets in lung cancer: Associations with drug resistance
Q83508020	Implications of personalized medicine--perspective from a cancer center
Q34838412	Importance of molecular features of non-small cell lung cancer for choice of treatment
Q38067427	Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer
Q38389841	Improving Clinical Trial Efficiency: Thinking outside the Box.
Q42545098	Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
Q42036423	Improving clinical trial efficiency by biomarker-guided patient selection
Q51281967	In Vitro Enzyme Kinetics Analysis of EGFR.
Q42758535	In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
Q35905204	In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: from mutational analysis to drug designing
Q47355906	In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.
Q54578263	In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database.
Q37270405	In situ Protein Detection for Companion Diagnostics
Q27014174	In vitro and in vivo models for analysis of resistance to anticancer molecular therapies
Q38905987	In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2.
Q37250640	In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
Q27853236	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
Q39701114	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Q38998235	In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growt
Q40031376	In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Q40290447	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib
Q40462593	Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.
Q60921926	Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression
Q36406111	Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.
Q35812244	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas
Q33999412	Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
Q38406514	Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Q38545768	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.
Q37141676	Incorporation of biologic therapies in the management of gastroesophageal cancers
Q36759284	Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing
Q36082004	Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
Q30279226	Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan
Q55425422	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Q39367306	Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer
Q36318541	Individualised cancer therapeutics: dream or reality?
Q36387788	Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
Q42535408	Individualization of treatment in non-small cell lung cancer
Q86073879	Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma
Q37579648	Individualized therapy in non-small-cell lung cancer: future versus current clinical practice
Q38260343	Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
Q26801711	Induced pluripotent stem cell technology for dissecting the cancer epigenome
Q37552307	Inducible Mouse Models for Cancer Drug Target Validation
Q36667008	Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells
Q36026392	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
Q37486272	Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition
Q34768930	Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice
Q24650438	Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound
Q90039016	Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
Q59794876	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Q35200458	Influence of chemotherapy on EGFR mutation status
Q37659062	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
Q51770090	Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer.
Q33586108	Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer
Q58804391	Inherited lung cancer syndromes targeting never smokers
Q46782213	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Q38970301	Inhibiting epidermal growth factor receptor at a distance
Q36764876	Inhibiting kinases in malignant gliomas
Q58207282	Inhibition of EGFR Signaling Protects from Mucormycosis
Q33227206	Inhibition of EGFR signaling: all mutations are not created equal
Q33571026	Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
Q38866417	Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
Q35261397	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis
Q36150646	Inhibition of angiogenesis in cancer patients
Q38852858	Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
Q33906140	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Q24810622	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
Q24301761	Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Q35528877	Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16
Q40210754	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
Q28079309	Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Q33925323	Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach
Q27851654	Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
Q37111609	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma
Q46613450	Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro
Q50866526	Initiation of a formalized precision medicine program in gynecologic oncology.
Q43807392	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Q37418930	Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review
Q34330521	Insulin-like growth factors and neoplasia.
Q37046462	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
Q37853183	Integrating biomarkers in clinical trials
Q28077310	Integrating cancer genomic data into electronic health records
Q33517983	Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?
Q43040968	Integrating molecular diagnostics into anticancer drug discovery.
Q26769744	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity
Q79227019	Integration of EGFR inhibitors with radiochemotherapy
Q38880324	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Q28271520	Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
Q38057720	Integration of phosphoproteomic, chemical, and biological strategies for the functional analysis of targeted protein phosphorylation
Q33673563	Integrative analysis of multi-omics data reveals distinct impacts of DDB1-CUL4 associated factors in human lung adenocarcinomas
Q33774682	Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients
Q38322114	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Q37216672	Integrative genomic approaches to understanding cancer.
Q30860315	Integrative modeling of multi-platform genomic data under the framework of mediation analysis
Q37301705	Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma.
Q35482150	Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance of human hepatic cancer HepG2/G cell line
Q39134067	Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression
Q46375753	Interaction maps for kinase inhibitors
Q33408501	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Q41437605	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
Q36474196	Interfering with cell-survival signalling as a treatment strategy for prostate cancer.
Q37689066	Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
Q38673369	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
Q28303718	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
Q52446289	Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status.
Q36029824	Interstitial lung disease in lung cancer: separating disease progression from treatment effects.
Q42278411	Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management
Q36544282	Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation.
Q91941020	Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement
Q37963231	Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
Q40005057	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Q35994416	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Q33700689	Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
Q24603941	Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells
Q36559630	Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.
Q26744339	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Q34273541	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
Q39131097	Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation
Q85857386	Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation
Q37736496	Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma
Q46547397	Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Q33821320	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Q42743773	Is EGFR expression important in non-small cell lung cancer?
Q41092945	Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
Q44607835	Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?
Q26798882	Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?
Q53060849	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Q37537093	Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Q33403165	Isolation of novel EGFR-specific VHH domains
Q33936071	It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy
Q35987345	JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor
Q39328532	JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
Q34879739	Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Q57909068	KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer
Q53242395	KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Q40542208	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma
Q37815135	KRAS and BRAF: drug targets and predictive biomarkers
Q21563446	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
Q37681051	KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling
Q37694808	KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
Q42950523	Keap1 mutations in lung cancer patients
Q55083559	Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.
Q41768010	Key drivers of biomedical innovation in cancer drug discovery
Q82150802	Keynote comment: reimbursement for molecularly targeted anticancer agents
Q46555496	Killing time for cancer cells
Q37060709	Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements
Q34307423	Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening
Q37332008	Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib
Q39347810	Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers
Q64965123	Knowledge base toward understanding actionable alterations and realizing precision oncology.
Q38390205	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review
Q37728989	L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites
Q35943143	L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report
Q64083382	LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR
Q43188970	LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Q64059672	LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features
Q38206271	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer
Q54296884	LUX-Lung: determining the best EGFR inhibitor in NSCLC?
Q37696232	LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Q58796615	Label-free real-time ultrasensitive monitoring of non-small cell lung cancer cell interaction with drugs
Q39400167	Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity
Q37755493	Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature
Q54562020	Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Q35753530	Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
Q35889673	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
Q36616712	Lack of clinical efficacy of imatinib in metastatic melanoma
Q36439293	Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung
Q46965909	Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer
Q50775865	Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
Q35831012	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations
Q90631641	Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma
Q55485409	Landscape of transcriptional deregulation in lung cancer.
Q55070923	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Q37059866	Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature
Q54486463	Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Q33358603	Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type
Q33788680	Leptomeningeal Carcinomatosis in Recurrent Non-Small Cell Lung Cancer: A Case Report and Review of Current Treatment Modalities
Q47133535	Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy
Q36851421	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
Q37810104	Lestaurtinib: a multi-targeted FLT3 inhibitor
Q37708018	Leveraging Genomic Factors to Improve Benefit-Risk
Q35965565	Leveraging protein quaternary structure to identify oncogenic driver mutations
Q52723140	Lgr5+ intestinal stem cells reside in an unlicensed G1 phase.
Q89762208	Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET
Q26797495	Ligand-Independent EGFR Signaling
Q36254464	Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses
Q35566222	Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression
Q26829104	Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
Q49684088	Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Q33931015	Limited importance of the dominant-negative effect of TP53 missense mutations
Q28253671	Lineage dependency and lineage-survival oncogenes in human cancer
Q38859701	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy
Q92028093	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
Q39279845	Liquid biopsy: unlocking the potentials of cell-free DNA.
Q37716622	Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
Q36904551	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
Q37179405	Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome
Q38734500	Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges
Q42366666	Long non-coding RNAs associated with non-small cell lung cancer
Q38682910	Long noncoding RNAs: emerging regulators of tumor angiogenesis
Q102057123	Long term follow-up of EGFR mutated NSCLC cases
Q53823427	Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Q34130681	Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
Q51147438	Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Q98466270	Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports
Q36916399	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Q89622158	Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints
Q49340076	Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Q49359622	Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance.
Q33977056	Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance
Q36028210	Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma
Q28481370	Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells
Q36503161	Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition
Q47653923	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
Q33779389	Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing
Q39970216	Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status
Q54440196	Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments.
Q92577499	Low-abundance mutations in colorectal cancer patients and healthy adults
Q38868797	Low-fidelity alternative DNA repair carcinogenesis theory may interpret many cancer features and anticancer strategies
Q39096391	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
Q36761452	Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications
Q39350278	Lung Cancer Epidemiology in Korea.
Q38679289	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Q28386607	Lung Cancer: Are we up to the Challenge?
Q53776017	Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
Q47127472	Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification
Q35887906	Lung adenocarcinoma and human papillomavirus infection
Q53534519	Lung adenocarcinoma and its thyroid metastasis characterized on fine-needle aspirates by cytomorphology, immunocytochemistry, and next-generation sequencing.
Q34281228	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases
Q33967404	Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
Q35790212	Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain
Q36962487	Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers
Q89579716	Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib
Q37438296	Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers
Q53403793	Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Q37147755	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Q34666826	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Q35207787	Lung cancer and lung injury: the dual role of ceramide
Q37487153	Lung cancer biology: a genetic and genomic perspective.
Q26775396	Lung cancer biomarkers, targeted therapies and clinical assays
Q33861083	Lung cancer cytology: potential pitfalls and mimics - a review
Q29615414	Lung cancer in never smokers--a different disease
Q58804388	Lung cancer in never smokers-the East Asian experience
Q34177155	Lung cancer in never smokers: molecular profiles and therapeutic implications
Q36026075	Lung cancer in never-smokers
Q35861107	Lung cancer in the era of precision medicine
Q44477692	Lung cancer in women: the differences in epidemiology, biology and treatment outcomes
Q39356534	Lung cancer samples preserved in liquid medium: One step beyond cytology
Q34541960	Lung cancer therapeutics that target signaling pathways: an update
Q38476124	Lung cancer treatment - Biology based decision, from gene to histology
Q37114965	Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
Q35667888	Lung cancer, thyroid cancer or both: An unusual case presentation
Q36328370	Lung cancer: Biology and treatment options
Q46049056	Lung cancer: New biological insights and recent therapeutic advances
Q37622985	Lung cancer: a biologically different disease in women?
Q87903213	Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC
Q34354426	Lung cancer: intragenic ERBB2 kinase mutations in tumours
Q39741320	Lung cancers unrelated to smoking: characterized by single oncogene addiction?
Q36140332	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Q34104798	Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke
Q37755025	Lung microRNA: from development to disease
Q36501975	Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers
Q54337332	M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.
Q37268998	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin
Q96431732	MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer
Q38051474	MEK and RAF inhibitors for BRAF-mutated cancers
Q37427045	MEK inhibitors against MET-amplified non-small cell lung cancer
Q42354586	MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Q42019758	MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Q35872321	MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model
Q36788312	MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
Q35606387	MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
Q28551045	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Q38709287	MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
Q27851406	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Q24646295	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Q37520331	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Q36140765	MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Q37399525	MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
Q38390016	MET inhibition in lung cancer
Q34033952	MET receptor sequence variants R970C and T992I lack transforming capacity
Q64929599	MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration.
Q35417648	ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.
Q35781614	MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
Q33570512	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
Q38803437	MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Q39311676	Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates
Q39293814	Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.
Q64054076	Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway
Q46070125	Making a difference with teamwork.
Q33846850	Making sense of cancer genomic data
Q90947631	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Q38089834	Malignant glioma drug discovery - targeting protein kinases
Q36499234	Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
Q35108421	Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma
Q54166640	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.
Q90300758	Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Q38685481	Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective
Q38258633	Management of NSCLC: focus on crizotinib
Q49887989	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.
Q26865779	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer
Q38131165	Management of non-small-cell lung cancer: recent developments
Q33892597	Management of patients with advanced non-small cell lung cancer: role of gefitinib
Q90167972	Managing Lung Cancer with Comorbid Interstitial Pneumonia
Q37003374	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Q34350615	Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery
Q37706977	Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2.
Q33398142	Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy
Q59800637	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Q52568478	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Q36682301	Mechanisms and insights into drug resistance in cancer
Q34277873	Mechanisms behind the inhibition of lung adenocarcinoma cell by shikonin
Q38459398	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Q37217229	Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers
Q28069900	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Q38669280	Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
Q42043613	Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
Q39185608	Mechanisms of Resistance to Immune Checkpoint Antibodies.
Q52312436	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Q50146512	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Q39308771	Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
Q38034816	Mechanisms of acquired resistance to targeted cancer therapies.
Q36559283	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
Q36953160	Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer
Q36472437	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Q39056242	Mechanisms of epidermal growth factor receptor signaling as characterized by patterned ligand activation and mutational analysis
Q35043706	Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer
Q36887721	Mechanisms of resistance to EGFR targeted therapies
Q28077415	Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Q39242812	Mechanisms of resistance to ErbB-targeted cancer therapeutics
Q37671920	Mechanisms of resistance to HER family targeting antibodies
Q28074073	Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Q97538337	Mechanisms of resistance to osimertinib
Q36942619	Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.
Q36573324	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
Q83390165	Mechanisms of tumor resistance to EGFR-targeted therapies
Q90333285	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective
Q39603355	Mechanistic insights into the activation of oncogenic forms of EGF receptor
Q36107597	Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound
Q98467275	Medical management of brain metastases
Q42190258	Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Q36772001	Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells
Q34749765	Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands
Q36249213	Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
Q36224439	Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma
Q30415408	Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells
Q39911616	Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Q34449385	Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
Q91646512	Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
Q36903072	Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Q35588724	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?
Q25257542	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
Q36031278	Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations
Q37871213	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
Q93379419	Metastatic osteosarcoma challenged by regorafenib
Q92597887	Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs
Q37848661	Methodological and practical challenges for personalized cancer therapies
Q36540555	Methodological aspects of current problems in target-based anticancer drug development
Q35925441	Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
Q42013793	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
Q38833904	MiR-122 Induces Radiosensitization in Non-Small Cell Lung Cancer Cell Line
Q37274389	MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Q37681498	MiRNA-125a-5p: a regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma
Q37702742	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
Q39433270	MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact
Q38826622	MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway
Q42315789	MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma
Q37723702	MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
Q36429673	MicroRNAs as a potential magic bullet in cancer.
Q38917573	MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.
Q37297730	MicroRNAs in the pathogenesis of Lung Cancer
Q42354892	MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer?
Q38430945	Microarray gene expression analysis of chemosensitivity for docetaxel, cisplatin and 5-fluorouracil (TPF) combined chemotherapeutic regimen in hypopharyngeal squamous cell carcinoma
Q34975977	Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile
Q26748947	Migraine in the era of precision medicine
Q39214395	Milestones in the systemic treatment of lung cancer
Q64936082	Miliary lung metastases from non-small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report.
Q48125418	Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.
Q34796086	Mind-mapping for lung cancer: towards a personalized therapeutics approach
Q33631471	Minireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung Cancer
Q35679203	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction
Q40467961	Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues.
Q37347485	Mitochondria: gatekeepers of response to chemotherapy
Q39890068	Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase
Q64298060	Mixed response to osimertinib and the beneficial effects of additional local therapy
Q36910615	Modeling NSCLC progression: recent advances and opportunities available
Q92531307	Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung Cancer
Q38721547	Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies
Q28484612	Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression
Q36840172	Modeling oncogene addiction using RNA interference.
Q89598805	Molecular Analysis of Liquid-Based Cytological Specimen Using Virtually Positive Sputum with Adenocarcinoma Cells
Q37120887	Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase
Q28070038	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective
Q58700723	Molecular Diagnostics in Clinical Oncology
Q35849985	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Q35216709	Molecular Imaging in Optical Coherence Tomography
Q34213559	Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
Q26771116	Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
Q42926986	Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells
Q37347532	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
Q37589551	Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities
Q38869420	Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Q47141828	Molecular Targets in Non-Small Cell Lung Cancer
Q38582997	Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review
Q55564375	Molecular Therapies in Thyroid Cancer.
Q38258822	Molecular alterations in non-small-cell lung cancer: perspective for targeted therapy and specimen management for the bronchoscopist
Q37683112	Molecular alterations in uterine serous carcinoma
Q37349875	Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
Q51019080	Molecular alterations of EGFR in small intestinal adenocarcinoma.
Q37350516	Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
Q46594292	Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
Q30811836	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes
Q38292199	Molecular analysis-based treatment strategies for non-small cell lung cancer
Q33843578	Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer
Q36993693	Molecular basis for multimerization in the activation of the epidermal growth factor receptor
Q36612550	Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Q24606677	Molecular biology of lung cancer
Q37653893	Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Q24610335	Molecular biology of lung cancer: clinical implications
Q36273001	Molecular biology of medulloblastoma: will it ever make a difference to clinical management?
Q33969308	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Q63366116	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’
Q34778891	Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project
Q35681816	Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
Q33475963	Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
Q89426902	Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
Q37666114	Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance
Q36240941	Molecular chess? Hallmarks of anti-cancer drug resistance
Q56795277	Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay
Q58053853	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
Q43805944	Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue
Q48458378	Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods.
Q37037132	Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers
Q43226909	Molecular diagnostics in lung carcinoma for therapy stratification
Q43690882	Molecular diagnostics of lung cancer in the clinic
Q36370600	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration
Q42822469	Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases
Q51099791	Molecular dynamics and pharmacophore modelling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC.
Q41144243	Molecular dynamics simulation analysis of the effect of T790M mutation on epidermal growth factor receptor protein architecture in non-small cell lung carcinoma
Q64265169	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare mutations
Q24611043	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
Q42951192	Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer
Q38117105	Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations
Q37206476	Molecular genetics of lung cancer in people who have never smoked
Q37732704	Molecular imaging and targeted therapies
Q48451660	Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
Q34534164	Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT
Q37061902	Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA
Q28544659	Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics
Q36673960	Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors
Q36634023	Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas
Q34560236	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
Q42290027	Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Q39411432	Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers
Q33828409	Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Q35104755	Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C.
Q38060727	Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors
Q35001415	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Q39172297	Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets
Q26769659	Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Q36567573	Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Q35256622	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond
Q36468815	Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
Q37602884	Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype
Q37919395	Molecular oncology of lung cancer
Q38012566	Molecular pathogenesis of malignant mesothelioma
Q38459875	Molecular pathology in oncology--the AstraZeneca perspective
Q34194997	Molecular pathology of lung cancer: current status and future directions
Q27691299	Molecular pathology of lung cancer: key to personalized medicine
Q27690919	Molecular pathology of non-small cell lung cancer: a practical guide
Q36868012	Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
Q37606747	Molecular predictive and prognostic markers in non-small-cell lung cancer.
Q36772562	Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer
Q36788498	Molecular predictors of chemotherapy response in non-small-cell lung cancer
Q36498832	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
Q33696507	Molecular profile of lung cancer in never smokers
Q92536292	Molecular profile of non-small cell lung cancer in northeastern Brazil
Q36691733	Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis
Q37417261	Molecular profiling of sinonasal undifferentiated carcinoma
Q54461448	Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer.
Q26830588	Molecular recognition of gangliosides and their potential for cancer immunotherapies
Q44070495	Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients
Q39214067	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
Q33609045	Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing
Q36944441	Molecular targeted therapies for pancreatic cancer
Q46780845	Molecular targeted therapy for lung cancer
Q36547758	Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
Q26828860	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors
Q34159011	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular
Q26824599	Molecular testing in lung cancer in the era of precision medicine
Q37771888	Molecular testing in lung cancer: the time is now.
Q92326347	Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Q34608584	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer
Q37458175	Molecular therapy in head and neck oncology
Q33699594	Molecular tumor board: the University of California-San Diego Moores Cancer Center experience
Q47130146	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
Q36929734	Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
Q36859958	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Q33644407	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies
Q35136424	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014
Q36829847	Molecularly targeted therapy for malignant glioma
Q36326239	Molecularly-targeted therapies for non-small cell lung cancer
Q46793091	Molecule-kinase interaction map.
Q35962944	Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR.
Q80100680	Monitoring EGFR-mutant lung cancers by means of the blood
Q35004426	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib
Q36514558	Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
Q47617131	Monoamines in Glioblastoma: complex biology with therapeutic potential.
Q37051227	Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer
Q33594324	Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib
Q38765690	Morphometric and cytomorphologic characterization of EGFR-mutated cancer cells-comparison between cultured lung cancer cell lines and lung adenocarcinoma clinical samples
Q36184798	Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients
Q38431277	Mouse hospital and co-clinical trial project--from bench to bedside.
Q36547732	Mouse models of human non-small-cell lung cancer: raising the bar.
Q47108604	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer
Q24683814	Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features
Q35541778	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience
Q82976088	Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy
Q84444587	Multicenter analysis of lung cancer patients younger than 45 years in Shanghai
Q36494159	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Q35799619	Multigene amplification and massively parallel sequencing for cancer mutation discovery
Q36936796	Multimodality imaging of the HER-kinase axis in cancer
Q34123261	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
Q35237841	Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
Q89747760	Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy
Q39246320	Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer
Q59807868	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
Q41986671	Multiplex Real-Time PCR Assays that Measure the Abundance of Extremely Rare Mutations Associated with Cancer
Q40479483	Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR.
Q35169273	Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry
Q37595545	Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine
Q91741802	Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
Q36163327	Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry
Q37633877	Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
Q37443767	Multiscale cancer modeling
Q51128947	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
Q59812799	Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients
Q89206835	Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples
Q52642806	Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis.
Q38804094	Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.
Q31162700	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
Q51437092	Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.
Q55004879	Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.
Q40149065	Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Q60445017	Mutation de l’EGFR, de l’étude du gène à la pratique clinique : exemplarité ou exception ?
Q33412122	Mutation detection by real-time PCR: a simple, robust and highly selective method
Q33856261	Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue
Q50613227	Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Q39813481	Mutation of epidermal growth factor receptor is associated with MIG6 expression
Q36383360	Mutation of the PIK3CA oncogene in human cancers
Q40237141	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients
Q43223369	Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias
Q34457501	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform
Q28484396	Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel
Q54373177	Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).
Q37512938	Mutation-associated fusion cancer genes in solid tumors.
Q97885892	Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
Q55281004	Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes.
Q36824808	Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
Q46881384	Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism
Q37558631	Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
Q54671910	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
Q33283995	Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4
Q35948040	Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients
Q34650735	Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1
Q41545847	Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients.
Q21261249	Mutational profiling of kinases in glioblastoma
Q41535851	Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease
Q33534522	Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer
Q34747189	Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India.
Q27851720	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer
Q24669579	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Q35558988	Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
Q37110011	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
Q36615150	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma
Q37823422	Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
Q80241919	Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer
Q37349031	Mutations in the polybasic juxtamembrane sequence of both plasma membrane- and endoplasmic reticulum-localized epidermal growth factor receptors confer ligand-independent cell transformation
Q46973585	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma
Q51051494	Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Q52892289	Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Q36121584	Mutations of the epidermal growth factor receptor gene in NSCLC patients
Q35551048	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
Q35380919	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells
Q34631703	N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines
Q38631853	NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Q64055892	NGFI-A Binding Protein 2 Promotes EGF-Dependent HNSCC Cell Invasion
Q92255821	NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells
Q38793074	NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
Q35063769	NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
Q27011692	Nanomedicine therapeutic approaches to overcome cancer drug resistance
Q57377197	Nanoparticles combined with growth factors: recent progress and applications
Q37822705	Nanoparticles for the development of improved (bio)sensing systems
Q28072745	Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes
Q24305218	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors
Q34551144	Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis
Q42292974	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance
Q38694837	Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer
Q38185175	Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor
Q47915799	Neoantigens in the immuno-oncology space
Q37603346	Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
Q33813119	Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases
Q28677268	Network-based drug discovery by integrating systems biology and computational technologies
Q37579308	Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Q55709770	Neuropeptide G Protein-Coupled Receptors as Oncotargets.
Q34483541	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib
Q45268799	Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival
Q92377401	New Era for Next-Generation Sequencing in Japan
Q39453653	New Insight into microRNA Functions in Cancer: Oncogene-microRNA-Tumor Suppressor Gene Network.
Q35088122	New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
Q38947183	New and emerging targeted treatments in advanced non-small-cell lung cancer.
Q38163931	New approach to cancer therapy based on a molecularly defined cancer classification.
Q52646651	New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Q36616537	New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children
Q58769699	New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey
Q47159366	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.
Q24680988	New molecularly targeted therapies for lung cancer
Q39139889	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
Q34998576	New prognostic factors and scoring system for patients with skeletal metastasis
Q26775385	New strategies in immunotherapy for non-small cell lung cancer
Q37724947	New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs
Q37080517	New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy
Q37853198	New targeted therapies for gastric cancer
Q42024692	New targets and challenges in the molecular therapeutics of cancer
Q37936432	New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology
Q24806486	New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors
Q38114835	New targets in non-small cell lung cancer
Q38949133	New therapeutic perspectives in CCDC6 deficient lung cancer cells
Q26746230	New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
Q28067439	Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients
Q39114552	Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
Q28079320	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
Q35726787	Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology
Q35078128	Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
Q34657670	Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.
Q60957062	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells
Q33779303	Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
Q39139857	Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
Q37558534	Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
Q34385995	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Q90747070	Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group
Q64244179	Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition
Q28730066	Non-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitro
Q52716935	Non-canonical functions of the RB protein in cancer.
Q39163315	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
Q100694461	Non-invasive detection of EGFR mutations by cell-free loop-mediated isothermal amplification (CF-LAMP)
Q36924440	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Q47146342	Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Q37874487	Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features
Q37859221	Non-small cell lung cancer in never-smokers: a new disease entity?
Q47139758	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.
Q34558586	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
Q26740333	Non-small cell lung cancer: current treatment and future advances
Q28278682	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
Q37645231	Non-small cell lung cancer: the era of targeted therapy
Q37692660	Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
Q36850900	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies
Q38233321	Non-small-cell lung cancers: a heterogeneous set of diseases
Q36622817	Noncovalent wild-type-sparing inhibitors of EGFR T790M
Q37321820	Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Q33735738	Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.
Q33909660	Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.
Q38865192	Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
Q26744284	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Q58790384	Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Q38999795	Novel [99mTcN]2+ labeled EGFR inhibitors as potential radiotracers for single photon emission computed tomography (SPECT) tumor imaging.
Q34389263	Novel agents in development for advanced non-small cell lung cancer
Q46255077	Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma
Q37923386	Novel approaches to treating leptomeningeal metastases
Q37772496	Novel biomarkers of metastatic cancer
Q38152899	Novel cancer therapies: treatments driven by tumour biology
Q39238873	Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors
Q34158952	Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations
Q36612451	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
Q28386773	Novel insights into the molecular origins and treatment of lung cancer
Q36045973	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
Q82562299	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
Q37702126	Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
Q37038500	Novel targets in non-small cell lung cancer: ROS1 and RET fusions
Q36187046	Novel therapeutics in adult malignant brain gliomas
Q51707848	Novel use for an EGFR mutation-specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia.
Q36864786	Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality
Q36798851	Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications
Q38810432	Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival
Q35063410	Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells
Q42431173	Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
Q46073617	O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.
Q36530038	Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer
Q41976220	Occupy EGFR.
Q50316870	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).
Q36108082	Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
Q90349512	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Q91761286	Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression
Q37188017	Omics and therapy - a basis for precision medicine
Q91238291	Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients
Q44945808	Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib
Q38355156	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Q35729391	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways
Q33510334	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells
Q36016428	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
Q35623817	Oncogenes come of age.
Q41009749	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.
Q36337966	Oncogenic PI3K deregulates transcription and translation
Q27852800	Oncogenic RIT1 mutations in lung adenocarcinoma
Q33902463	Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
Q45916835	Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Q47147399	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
Q38213830	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Q33943421	Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy
Q34073766	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma
Q24321210	Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization
Q24810573	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
Q37295261	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy
Q37782592	Oncomutations as biomarkers of cancer risk.
Q37069689	Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
Q38520010	Opportunities and challenges in using studies without a control group in comparative effectiveness reviews
Q36883671	Optimal duration of chemotherapy in advanced non-small cell lung cancer
Q37822780	Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
Q26859993	Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor
Q36406541	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling
Q37756959	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer
Q38405477	Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
Q36354945	Optimized expression-based microdissection of formalin-fixed lung cancer tissue.
Q36430307	Optimizing chemotherapy and targeted agent combinations in NSCLC.
Q53088478	Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
Q36441490	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
Q35112467	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer
Q39128273	Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer
Q37996453	Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer
Q28652806	Organizing knowledge to enable personalization of medicine in cancer
Q28083032	Organoid development in cancer genome discovery
Q47131461	Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling.
Q54213250	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Q38790929	Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Q39002726	Osimertinib for the treatment of non-small cell lung cancer
Q33757134	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Q38598893	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Q38991958	Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Q54959395	Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.
Q35368205	Our changing view of the genomic landscape of cancer
Q35584972	Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
Q51317673	Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Q50122983	Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Q45936261	Outpacing cancer.
Q38040628	Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
Q81578551	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study
Q36750945	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
Q37057914	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Q58599659	Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Q42716087	Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients
Q40996325	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma
Q26745427	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
Q36812355	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
Q26795556	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
Q37357692	Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists
Q48301559	Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Q24678516	Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation
Q36615322	Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability
Q37619679	Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
Q37157333	Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan
Q37579644	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
Q35763328	Overview of the development of personalized genomic medicine and surgery
Q36690248	Overview of the pharmacoeconomics of pharmacogenetics
Q86506613	PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples
Q37013280	PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
Q47124504	PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
Q42942636	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor
Q50326521	PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?
Q35653992	PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.
Q37039348	PI3K signaling in glioma--animal models and therapeutic challenges
Q35808438	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Q34028766	PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001
Q36545534	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Q54360869	PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Q38584695	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Q34616536	PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells
Q33987852	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
Q39826662	PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering
Q38087648	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Q38732488	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis
Q38629644	PTEN and PI3K/AKT in non-small-cell lung cancer.
Q44846498	PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Q39398876	PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS.
Q36788450	Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer
Q36487089	Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety
Q36900261	Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
Q37398845	Parameters for individualizing systemic therapy in non-small cell lung cancer
Q35584647	Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects
Q88790399	Past, present and future of gene expression-tailored therapy for lung cancer
Q37389526	Pathogenesis of lung cancer signalling pathways: roadmap for therapies
Q36233709	Pathogenesis of lung cancer: 100 year report
Q34781357	Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
Q44507827	Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
Q47895107	Patient selection criteria and the FLEX Study
Q40340984	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?
Q28080046	Patient-derived tumour xenografts for breast cancer drug discovery
Q39377749	Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors
Q64267035	Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer
Q93136766	Patterns of brain metastasis in anaplastic lymphoma kinase - rearranged and epidermal growth factor receptor-mutated lung cancer patients in magnetic resonance imaging
Q36334789	Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region
Q41559395	Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations.
Q48322740	Paul Ehrlich's magic bullet concept: 100 years of progress
Q36273006	Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches
Q80671770	Pediatric oncology
Q36187075	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Q47952924	Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
Q55070748	Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.
Q36187118	Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Q40013710	Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Q38176989	Peptide nucleic acids: a review on recent patents and technology transfer
Q33520512	Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications
Q53338991	Percutaneous computed tomography-guided lung biopsy and pleural dissemination: an assessment by intraoperative pleural lavage cytology.
Q46862765	Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology
Q34235130	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study
Q36462861	Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).
Q40479158	Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC).
Q64354468	Personalised Medicine: The Odyssey from Hope to Practice
Q36089579	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Q39453553	Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies
Q37965048	Personalized cancer medicine and the future of pathology.
Q38976521	Personalized learning: From neurogenetics of behaviors to designing optimal language training
Q37651778	Personalized management of chronic obstructive pulmonary disease via transcriptomic profiling of the airway and lung.
Q36441548	Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Q37932029	Personalized medicine for lung cancer: new challenges for pathology
Q35757107	Personalized medicine for pathological circadian dysfunctions
Q36817080	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
Q35680026	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Q37921595	Personalized medicine in lung cancer: what we need to know.
Q57177486	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Q51828510	Personalized medicine in oncology: the future is now.
Q74441598	Personalized medicine: Special treatment
Q42697296	Personalized medicine: hype or reality
Q38232150	Personalized oncology: genomic screening in phase 1.
Q37214412	Personalized prediction of EGFR mutation-induced drug resistance in lung cancer.
Q27027259	Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014
Q36321826	Personalized targeted therapy for lung cancer
Q58792324	Personalized therapy for lung cancer: Striking a moving target
Q37996505	Personalized therapy for non-small cell lung cancer: which drug for which patient?
Q35911350	Personalized therapy in endometrial cancer: challenges and opportunities
Q38266308	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
Q28075800	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Q36015295	Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST
Q27851614	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer
Q37080513	Personalizing lung cancer prevention through a reverse migration strategy
Q36811453	Personalizing therapy in advanced non-small cell lung cancer
Q35679361	Personalizing therapy with targeted agents in non-small cell lung cancer
Q47240432	Perspective: The clinical trial barriers
Q43061648	Perspectives in adjuvant chemotherapy in NSCLC.
Q36163982	Perspectives on novel therapies for bronchial carcinoma
Q39940683	Perspectives on the development of imatinib and the future of cancer research
Q28537769	Perturbation biology: inferring signaling networks in cellular systems
Q24339394	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Q34042708	Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity
Q28382921	PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor
Q28278381	Pharmacodynamic biomarkers for molecular cancer therapeutics
Q37194753	Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines
Q35889619	Pharmacogenetics - five decades of therapeutic lessons from genetic diversity
Q35889605	Pharmacogenetics and drug development: the path to safer and more effective drugs
Q40218486	Pharmacogenetics and stomach cancer: an update.
Q36478845	Pharmacogenetics approach to therapeutics
Q35038056	Pharmacogenetics in drug development
Q37275470	Pharmacogenetics in drug discovery and development: a translational perspective
Q36256445	Pharmacogenetics in gastrointestinal tumors
Q36493347	Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment.
Q35840645	Pharmacogenetics in type 2 diabetes: potential implications for clinical practice
Q38010747	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications
Q23919667	Pharmacogenetics, pharmacogenomics, and individualized medicine
Q36294685	Pharmacogenetics/genomics and personalized medicine
Q37430384	Pharmacogenetics: implementing personalized medicine
Q38262008	Pharmacogenomic biomarkers for personalized cancer treatment.
Q28392982	Pharmacogenomic discovery using cell-based models
Q35873676	Pharmacogenomics and stomach cancer.
Q38596926	Pharmacogenomics in the treatment of lung cancer: an update
Q27025558	Pharmacogenomics of chemotherapeutic susceptibility and toxicity
Q36966043	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies
Q56446183	Pharmacogenomics steps toward personalized medicine
Q35876017	Pharmacogenomics: bench to bedside
Q36658763	Pharmacogenomics: challenges and opportunities
Q36465177	Pharmacogenomics: from bedside to clinical practice
Q37353853	Pharmacokinetic considerations for new targeted therapies.
Q46375104	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.
Q37492540	Pharmacologic and chemical adjuvants in tumor virotherapy
Q39396274	Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
Q37822760	Pharmacometabonomics as an effector for personalized medicine.
Q38248997	Pharmacotherapy targeting the EGFR oncogene in NSCLC.
Q33161299	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Q53545682	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Q49962860	Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
Q45904308	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Q37069238	Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Q50933613	Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Q91796969	Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Q36317627	Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma
Q35527148	Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
Q43092698	Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer
Q34549722	Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer
Q36938818	Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Q34578584	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
Q64107367	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ()-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California
Q37705422	Phase II clinical trials in oncology: are we hitting the target?
Q42162257	Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy
Q33390208	Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
Q36614114	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Q52941341	Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Q44656784	Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Q34427320	Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
Q37693919	Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
Q54403335	Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Q36625206	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
Q33608491	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
Q51493357	Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Q46791717	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Q35208151	Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
Q42663635	Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Q37414810	Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
Q47723850	Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations
Q94545721	Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer
Q35256618	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer
Q36642695	Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours
Q36346828	Phosphoinositide 3-kinase: from viral oncoprotein to drug target
Q38757884	Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Q36219744	Phosphoproteomics for oncology discovery and treatment
Q34539788	Phosphoproteomics in cancer
Q27851872	Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Q36717778	Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer
Q35082185	Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors
Q24644787	Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors
Q39561256	Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells
Q34598322	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.
Q54503313	Phosphorylation of epidermal growth factor receptor and chromosome 7 polysomy in gastric adenocarcinoma.
Q38943113	Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma.
Q36524232	Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer
Q36962642	Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling
Q34039413	Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib
Q47387077	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers
Q36558400	Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Q39089524	Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors
Q35187806	Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
Q42835389	Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas
Q35996716	Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells
Q54961209	Pituitary-Directed Therapies for Cushing's Disease.
Q45998326	Placental overgrowth and fertility defects in mice with a hypermorphic allele of epidermal growth factor receptor.
Q51239492	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Q36020891	Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity
Q36632245	Point mutations of protein kinases and individualised cancer therapy
Q51415798	Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Q36385082	Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients
Q28757672	Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers
Q35800638	Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.
Q37623532	Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Q51029938	Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
Q34311186	Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
Q36905639	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Q89493481	Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
Q37528486	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
Q42340129	Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.
Q43515674	Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer
Q28394485	Population-based trends in lung cancer incidence in women
Q26778987	Positional proteomics in the era of the human proteome project on the doorstep of precision medicine
Q36420719	Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology
Q27026940	Positron emission tomography to assess hypoxia and perfusion in lung cancer
Q36439506	Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma
Q99565904	Postoperative management for non-small cell lung cancer harboring EGFR mutations
Q95723908	Postoperative survival According to the Glasgow Prognostic Score in Patients with Resected Lung Adenocarcinoma
Q36537788	Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics
Q35941562	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model.
Q26775315	Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives
Q33520624	Power to detect selective allelic amplification in genome-wide scans of tumor data
Q38555223	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon
Q47597667	Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics
Q89429141	Pragmatic approaches to address expansion cohort design
Q35702897	Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
Q89975407	Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
Q33714064	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Q38838757	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
Q50195535	Precision Oncology: The Road Ahead.
Q38810911	Precision medicine in pediatric oncology: Lessons learned and next steps
Q47566249	Precision medicine: does ethnicity information complement genotype-based prescribing decisions?
Q52857191	Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
Q40373819	Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Q27322080	Preclinical mouse cancer models: a maze of opportunities and challenges
Q40365247	Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer
Q36547786	Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors
Q37209222	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Q34572279	Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia
Q36788485	Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
Q36042375	Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM
Q33247966	Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development
Q35151544	Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers
Q40053178	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics
Q40327150	Prediction of anticancer drug potency from expression of genes involved in growth factor signaling
Q43162278	Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer
Q45248889	Prediction of response to tyrosine kinase epithelial cell growth factor receptor inhibitors: a major breakthrough in the treatment of non-small-cell lung cancer
Q45116933	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Q51743342	Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Q57896476	Predictive Tumor Biomarkers for EGFR Inhibitors
Q34620545	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation
Q35076206	Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer
Q33311133	Predictive and prognostic markers in neuro-oncology
Q38137764	Predictive biomarkers for cancer therapy with PARP inhibitors.
Q26824536	Predictive biomarkers in precision medicine and drug development against lung cancer
Q46066416	Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.
Q52991200	Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Q35077521	Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma
Q36610291	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
Q35773852	Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow
Q34427439	Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
Q39028004	Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer
Q37579647	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer
Q54510031	Predictive value of loci in VEGF pathway genes in bevacizumab treatment.
Q47143835	Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.
Q36808416	Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study
Q81601035	Predominance of high-grade pathway in breast cancer development of Middle East women
Q35145369	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Q94371037	Preface
Q36088722	Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer
Q30890447	Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma
Q41869566	Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies
Q51168062	Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.
Q35877737	Present status and problems on molecular targeted therapy of cancer
Q35478632	Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
Q35671830	Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
Q45370579	Prevalence and detection of low-allele-fraction variants in clinical cancer samples.
Q36330709	Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
Q38661269	Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population
Q39073840	Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review
Q41461334	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis
Q36085837	Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
Q60949785	Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer
Q92107648	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region
Q54384637	Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma.
Q36654338	Prevention of breast cancer: current state of the science and future opportunities
Q38745430	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Q38008698	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update
Q37799825	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer
Q27009148	Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer
Q39649266	Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up
Q36180606	Priorities and standards in pharmacogenetic research
Q43259078	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs
Q38262620	Prioritizing targets for precision cancer medicine
Q38694064	Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma.
Q38470647	ProKinO: a unified resource for mining the cancer kinome
Q92282893	Profile of Daniel A. Haber
Q39106800	Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Q51139197	Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Q21562343	Profiling critical cancer gene mutations in clinical tumor samples
Q92767063	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors
Q37652622	Prognosis of recurrent non-small cell lung cancer following complete resection
Q91906497	Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
Q38089884	Prognostic and predictive factors in resected non-small-cell lung cancer
Q34443983	Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial
Q38019976	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer
Q38493294	Prognostic and predictive value of MET deregulation in non-small cell lung cancer
Q30498101	Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer
Q54632156	Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Q33620091	Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
Q34616626	Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer
Q48551119	Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Q44462744	Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer
Q55035103	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study.
Q37702165	Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial
Q34544677	Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Q38399545	Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
Q36399028	Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
Q34860000	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study
Q46620066	Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
Q46416422	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Q35681087	Prognostic role of p53 and Ki-67 immunohistochemical expression in patients with surgically resected lung adenocarcinoma: a retrospective study
Q34775815	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma
Q34181641	Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease
Q45751366	Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma.
Q54485965	Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma.
Q90087574	Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer
Q34937417	Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy
Q51678342	Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Q41296140	Prognostic value of LIPC in non-small cell lung carcinoma
Q47547523	Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.
Q46757816	Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas
Q27692669	Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis
Q37902246	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
Q49163406	Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Q35632548	Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
Q44171169	Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance
Q41956993	Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
Q36838905	Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report
Q36235591	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity
Q33283634	Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers
Q28294647	Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)
Q36095223	Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Q37483993	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
Q35975657	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
Q53573913	Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Q41970534	Prospective, high-throughput molecular profiling of human gliomas
Q37775627	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations
Q34554617	Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents
Q54518974	Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
Q35208584	Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer
Q38205518	Protein kinase inhibitors to treat non-small-cell lung cancer
Q37417742	Protein kinase inhibitors: contributions from structure to clinical compounds
Q51540449	Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
Q24337213	Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells
Q36969009	Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
Q38461516	Proteome research in urothelial carcinoma.
Q35814785	Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response
Q36168391	Proteomic analysis of cellular signaling
Q37709355	Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor
Q39282659	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Q39868726	Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Q30402667	Proteomics and biomarkers in clinical trials for drug development
Q33233797	Proteomics: clinical applications for head and neck squamous cell carcinoma
Q64269953	Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Q92951808	Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target
Q90383683	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity
Q53190932	Pulmonary adenocarcinoma with epidermal growth factor receptor-mutations in asbestos exposed non-smokers: A case series.
Q28395348	Pulmonary adenocarcinoma: a renewed entity in 2011
Q34404209	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification
Q34284660	Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
Q38658503	Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer
Q36051542	Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial
Q28541305	Quantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substances
Q54979720	Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes.
Q37480093	Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
Q37190448	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Q34158755	Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array
Q37210782	Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer
Q60307896	Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states
Q90292140	Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study
Q37330722	Quantitative modeling perspectives on the ErbB system of cell regulatory processes
Q37340472	Quantitative prediction of fold resistance for inhibitors of EGFR.
Q37649220	Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
Q98386425	Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas
Q35138060	Quantum coupled mutation finder: predicting functionally or structurally important sites in proteins using quantum Jensen-Shannon divergence and CUDA programming.
Q42633890	Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies
Q34143354	Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer
Q90447993	R-spondin family members as novel biomarkers and prognostic factors in lung cancer
Q37399367	RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer
Q34138262	RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?
Q37065818	RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Q36530631	RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
Q37650677	RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
Q46700376	RETRACTED: Ca(2+)/calmodulin-dependent protein kinase IIγ, a critical mediator of the NF-κB network, is a novel therapeutic target in non-small cell lung cancer
Q35461504	RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody
Q40484644	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M.
Q33569727	RNA interference and nonviral targeted gene therapy of experimental brain cancer
Q35934254	RNAi and HTS: exploring cancer by systematic loss-of-function
Q37187716	RNAi screen for rapid therapeutic target identification in leukemia patients
Q33306326	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia
Q41985336	RNAi-induced synthetic lethality in cancer therapy
Q36946705	ROS1 copy number alterations are frequent in non-small cell lung cancer
Q43101538	ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission
Q27851700	ROS1 rearrangements define a unique molecular class of lung cancers
Q39325857	RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.
Q38178095	Race and ethnicity in cancer therapy: what have we learned?
Q40340394	Race, gender and mutations in the prediction of anti-EGFR activity
Q36440803	Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers
Q52985571	Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
Q40409078	Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?
Q60922021	Radiogenomics as association between non-invasive imaging features and molecular genomics of lung cancer
Q36634305	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
Q33673131	Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma
Q35814752	Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study
Q38564088	Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors
Q35810510	Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
Q50300068	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Q36951721	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer
Q49928885	Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
Q37290704	Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer
Q37658881	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
Q35817772	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoc
Q37104233	Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Q37594039	Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results
Q33407127	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Q38410994	Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis
Q41956182	Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay
Q33872030	Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer
Q39661497	Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons
Q40026743	Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).
Q37185267	Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3.
Q89116419	Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes
Q35789960	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas
Q42204869	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Q37404105	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Q90484072	Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch
Q47864863	Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
Q38730141	Rare cancers: a sea of opportunity
Q90343085	Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Q38104414	Rare mutations in non-small-cell lung cancer
Q42506718	Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
Q46466221	Rare subtypes of adenocarcinoma of the lung
Q37672002	Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists
Q34773458	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Q36046225	Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies
Q92282031	Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma
Q46486238	Rationale for combination use of targeted agents in ovarian cancer: do we have one?
Q38514601	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
Q36085487	Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment
Q42945763	Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report
Q36372611	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
Q36050294	Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
Q92326226	Real-time PCR and targeted next-generation sequencing in the detection of low level EGFR mutations: Instructive case analyses
Q47102256	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.
Q36729611	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
Q37458182	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials
Q42004900	Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures
Q34762839	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
Q43611330	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Q38672650	Recent Advances in Conjugated Polymer Materials for Disease Diagnosis
Q39079553	Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
Q34678073	Recent advances in personalized lung cancer medicine
Q40143039	Recent advances in targeted advanced lung cancer therapy in the elderly
Q36709566	Recent advances in targeted therapy for non-small cell lung cancer.
Q36318531	Recent advances in targeted therapy of human myelogenous leukaemia
Q36491838	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain
Q28070120	Recent advances in the biology of human circulating tumour cells and metastasis
Q88487552	Recent advances in the management of lung cancer
Q47105316	Recent advances in the management of non-small cell lung cancer
Q21092930	Recent advances of novel targeted therapy in non-small cell lung cancer
Q36874335	Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.
Q36636637	Recent developments in the chemotherapeutic options for nonsmall cell lung cancer
Q51106997	Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
Q36492444	Recent trends in the treatment of advanced lung cancer
Q38023942	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Q91310921	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Q58607138	Receptor Tyrosine Kinase-Targeted Cancer Therapy
Q37368256	Receptor signaling as a regulatory mechanism of DNA repair
Q37831148	Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma
Q27851674	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Q28082793	Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Q36738608	Receptor tyrosine kinases: mechanisms of activation and signaling
Q46047035	Receptor-based predictors of response in breast cancer
Q35102025	Receptor-tyrosine-kinase-targeted therapies for head and neck cancer
Q37194503	Recurrent gene fusions in prostate cancer
Q37118936	Recurrent head and neck cancer: current treatment and future prospects.
Q37262314	Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment
Q57806346	Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens
Q51587643	Reducing experimental variability in variance-based sensitivity analysis of biochemical reaction systems.
Q40426911	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Q35957585	Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis
Q38473472	Refining the treatment of NSCLC according to histological and molecular subtypes
Q37645169	Refining the treatment of advanced nonsmall cell lung cancer.
Q28603408	Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Q37226800	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Q37096248	Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains
Q36738312	Regulation of MAPKs by growth factors and receptor tyrosine kinases
Q35206258	Regulation of cell transformation by Rb-controlled redox homeostasis
Q38074713	Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments
Q28391395	Reinventing diagnostics for personalized therapy in oncology
Q83964708	Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade
Q33634703	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
Q37183593	Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer
Q50989318	Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Q37058782	Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations with the influence on the prognosis of non-small-cell lung cancer patients
Q36341825	Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer
Q35791117	Relevant molecular markers and targets
Q54561641	Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Q54120286	Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review.
Q41767944	Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report
Q36307379	Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation
Q35166782	Renal cell carcinoma and the use of sorafenib
Q38581146	Renal toxicity of anticancer agents targeting HER2 and EGFR.
Q36741917	Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma
Q24658420	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
Q35063579	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients
Q34185518	Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study
Q58792355	Requirement for MUC5AC in KRAS-dependent lung carcinogenesis
Q36330264	Research progress on criteria for discontinuation of EGFR inhibitor therapy
Q36113804	Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer
Q27853298	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Q53718494	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
Q37487158	Resistance mechanisms of tumour cells to EGFR inhibitors
Q47715159	Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
Q42557873	Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Q51004850	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Q34392733	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer
Q38930367	Resistance to Therapy
Q38626744	Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies
Q55191884	Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
Q79443198	Resistance to gefitinib
Q37715457	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway
Q26739760	Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
Q41634338	Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC
Q38012422	Respiratory cytology in the era of molecular diagnostics: a review
Q38931077	Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review
Q46941491	Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
Q33576476	Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Q36225230	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha
Q28306934	Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation
Q29618727	Restoration of p53 function leads to tumour regression in vivo
Q44843905	Restriction endonuclease-mediated real-time digestion-PCR for somatic mutation detection
Q58417919	Results of the UK NEQAS for Molecular Genetics reference sample analysis
Q33881153	Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition
Q84723308	Retrospective subset analyses in early breast cancer revisited
Q24611142	Retroviral oncogenes: a historical primer
Q54794454	Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Q36041152	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer
Q34180683	Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
Q37290444	Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Q27015079	Review of the current targeted therapies for non-small-cell lung cancer
Q34449725	Review of the regulations for clinical research in herbal medicines in USA.
Q36461805	Review of the treatment of non-small cell lung cancer with gefitinib
Q37093554	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Q35668629	Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.
Q36015618	Rhizoma Paridis Saponins Induces Cell Cycle Arrest and Apoptosis in Non-Small Cell Lung Carcinoma A549 Cells
Q36413425	Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
Q57918768	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese
Q37697247	Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
Q35584486	Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer
Q38818845	Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Q38486882	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.
Q54980093	Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
Q37153625	Role of ErbB4 in breast cancer
Q38087392	Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Q26781683	Role of HER2 in NSCLC
Q53711253	Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
Q35067488	Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors
Q54340378	Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Q36622102	Role of deltaNp63(pos)CD44v(pos) cells in the development of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse lung squamous cell carcinomas.
Q37320346	Role of epidermal growth factor receptor in breast cancer
Q36155957	Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer
Q36475391	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action
Q34417886	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Q35919264	Role of erlotinib in the management of pancreatic cancer.
Q37591935	Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
Q26866485	Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
Q26750428	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
Q37956397	Role of genotyping in non-small cell lung cancer treatment: current status
Q92134595	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer
Q27027957	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents
Q36950439	Role of miRNA in carcinogenesis and biomarker selection: a methodological view
Q33576845	Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer
Q36616926	Role of novel targeted therapies in the clinic
Q50050619	Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer.
Q37288681	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Q28242840	Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy
Q34705858	Roles for growth factors in cancer progression
Q35111284	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer
Q36477469	Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Q37627937	Roles of pathologists in molecular targeted cancer therapy
Q41605055	Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?
Q33599057	Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing
Q40096915	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Q36695771	S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas
Q100512512	S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
Q84706708	SEOM clinical guidelines for using molecular markers in clinical practice
Q38833666	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Q37246242	SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers
Q28818608	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers
Q41876194	SMC1A knockdown induces growth suppression of human lung adenocarcinoma cells through G1/S cell cycle phase arrest and apoptosis pathways in vitro
Q34989327	SNP (-617C>A) in ARE-like loci of the NRF2 gene: a new biomarker for prognosis of lung adenocarcinoma in Japanese non-smoking women
Q41642309	SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer
Q37662776	SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner
Q35570442	SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines
Q30821792	STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
Q47412228	Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study
Q44555068	Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation
Q46764329	Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer
Q43965995	Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Q38841473	Safety of gefitinib in non-small cell lung cancer treatment
Q38786021	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
Q37364638	Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
Q58704176	Score for lung adenocarcinoma in China with EGFR mutation of exon 19: Combination of clinical and radiological characteristics analysis
Q34497010	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study
Q34032012	Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
Q40251351	Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells
Q30488528	SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome
Q37177594	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
Q93185180	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
Q36904574	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers
Q36268315	Second-generation kinase inhibitors
Q38155201	Second-line systemic therapy for metastatic urothelial carcinoma of the bladder
Q47861831	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Q80100973	Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Q37945643	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
Q53854603	Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.
Q90468769	Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients
Q44915706	Selecting the right patient for tumor therapy
Q37730020	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers
Q41678123	Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors
Q34384968	Selection of extreme phenotypes: the role of clinical observation in translational research.
Q58151801	Selective Energy Transfer Between Quantum Dots and Gold Nanoparticles for Detection of Multiple Mutations in Epidermal Growth Factor Receptor
Q34354339	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
Q47226790	Selective heat generation in cancer cells using a combination of 808 nm laser irradiation and the folate-conjugated Fe2O3@Au nanocomplex.
Q36616873	Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
Q40862682	Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.
Q61456218	Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells
Q51293195	Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples.
Q36746316	Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells
Q79787202	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
Q35189160	Sensitivity analysis of biological Boolean networks using information fusion based on nonadditive set functions
Q37468539	Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies
Q36611196	Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
Q33510934	Sequence and structure signatures of cancer mutation hotspots in protein kinases
Q34201724	Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975
Q91704405	Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers
Q37378176	Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung
Q33995172	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status
Q34614608	Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer
Q36695530	Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
Q90409971	Serum Platelet-Derived Growth Factor Is Significantly Lower in Patients with Lung Cancer and Continued to Decrease After Platinum-Based Chemotherapy
Q55011252	Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer.
Q46946875	Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas
Q54680146	Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Q54977786	Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.
Q35034044	Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
Q36839768	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors
Q40201980	Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats
Q37401172	Sex-specific aspects of tumor therapy
Q39194466	Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer
Q41701853	Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells
Q58759414	Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
Q37411082	Should primary tumor be resected for non-small cell lung cancer with malignant pleural disease unexpectedly found during operation?-a systemic review and meta-analysis
Q37847104	Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
Q27027778	Signaling cross-talk in the resistance to HER family receptor targeted therapy
Q35987785	Signaling multiplex of the epidermal growth factor receptor
Q36392991	Signaling networks assembled by oncogenic EGFR and c-Met
Q34072567	Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo
Q38805800	Signatures of drug sensitivity in nonsmall cell lung cancer
Q64250706	Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma
Q34886787	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
Q34427354	Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice
Q37034341	Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
Q89497005	Silence of S1 RNA binding domain 1 represses cell growth and promotes apoptosis in human non-small cell lung cancer cells
Q28547292	Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma
Q36216766	Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer
Q43860596	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
Q36782324	Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy
Q34589774	Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Q40472879	Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci
Q52583236	Single Locked Nucleic Acid-Enhanced Nanopore Genetic Discrimination of Pathogenic Serotypes and Cancer Driver Mutations.
Q34523257	Single-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off Probes
Q83015772	Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck
Q91721637	Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers
Q28069454	Skin problems and EGFR-tyrosine kinase inhibitor
Q39637704	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor
Q48070194	Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation
Q27027835	Small molecule compounds targeting the p53 pathway: are we finally making progress?
Q38219688	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Q37238413	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Q46971338	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
Q35602124	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment
Q37502708	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
Q36200850	Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.
Q37294797	Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates
Q99607554	Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing
Q36014517	Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report
Q46880458	Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma
Q24648102	Somatic mutations affect key pathways in lung adenocarcinoma
Q42706743	Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma
Q52590998	Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Q38512879	Somatic mutations of the ERBB4 kinase domain in human cancers
Q24648133	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer
Q37235024	Somatic pharmacogenomics in cancer
Q35749438	Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas
Q36028660	Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
Q33582914	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Q38020917	Sorafenib in non-small cell lung cancer
Q36708741	Sorafenib: where do we go from here?
Q39202557	Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs
Q33405933	Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma
Q39714753	Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report
Q37995451	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.
Q40127625	Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
Q40669345	Specific killing of Rb mutant cancer cells by inactivating TSC2.
Q89750470	Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis
Q35036895	Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients
Q36815913	Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
Q47930093	Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer
Q33563803	Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas
Q30837003	SpliceNet: recovering splicing isoform-specific differential gene networks from RNA-Seq data of normal and diseased samples
Q37137372	Sputum-based molecular biomarkers for the early detection of lung cancer: limitations and promise
Q30278774	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
Q39033091	Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
Q35207876	Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells
Q47390697	Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Q35167923	Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer
Q52673091	Standardizing biomarker testing for Canadian patients with advanced lung cancer.
Q36271949	State of the art in therapy for non-small cell lung cancer
Q34681069	State of the art: Response assessment in lung cancer in the era of genomic medicine
Q34089332	State-of-the-art MS technology applications in lung disease.
Q36269651	Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study
Q36117881	Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
Q84623471	Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC
Q37856721	Strategies to improve radiotherapy with targeted drugs
Q38838227	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR.
Q35968384	Strategies to overcome resistance to targeted protein kinase inhibitors
Q35017477	Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
Q54957856	Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance.
Q42119491	Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors
Q33810641	Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
Q27677383	Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
Q41593246	Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
Q90179057	Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
Q52345422	Structural insights into drug development strategy targeting EGFR T790M/C797S.
Q35652106	Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships
Q42768815	Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Q36181814	Structural systems biology and multiscale signaling models
Q92658888	Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing
Q27680966	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Q92934599	Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
Q37122918	Structure and clinical relevance of the epidermal growth factor receptor in human cancer
Q33680363	Structure and function of epigen, the last EGFR ligand
Q33812445	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
Q49344251	Structure-based pharmacophore design and virtual screening for novel potential inhibitors of epidermal growth factor receptor as an approach to breast cancer chemotherapy.
Q38987589	Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Q27643967	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
Q27644014	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Q40694780	Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
Q37389611	Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial
Q35700405	Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer
Q35929525	Studying a complex tumor: potential and pitfalls
Q35596310	Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Q37127423	Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Q89995873	Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations
Q44574005	Subtyping of pulmonary adenocarcinoma in cytologic specimens: the next challenge
Q36324363	Successes and failures of the teachable moment: smoking cessation in cancer patients
Q38721743	Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
Q44126874	Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population
Q38721555	Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
Q61798869	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Q28477887	Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis
Q37179584	Surgical treatment for primary pulmonary lymphoepithelioma-like carcinoma
Q36439350	Surgical treatment for pulmonary pleomorphic carcinoma: A retrospective study of 60 patients
Q47417911	Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib
Q40315977	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities
Q54977347	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
Q30574736	Survival and death signals can predict tumor response to therapy after oncogene inactivation
Q36311791	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Q51785555	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Q37761935	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
Q49873962	Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations.
Q54375452	Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer.
Q45041454	Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Q41969702	Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Q33837881	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy
Q49387613	Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.
Q39388106	Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway
Q40409431	Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
Q39429719	Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo
Q39499521	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation
Q39280914	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma
Q44851135	Synthesis and anticancer activity of new quinazoline derivatives
Q33847057	Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents
Q28820988	Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents
Q39413333	Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer
Q38801969	Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites
Q36539506	Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach
Q35854835	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB).
Q89900731	Systematic comparison of somatic variant calling performance among different sequencing depth and mutation frequency
Q33826328	Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues
Q29547695	Systematic identification of genomic markers of drug sensitivity in cancer cells
Q37331472	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
Q58774943	Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma
Q34865629	Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer
Q54978262	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
Q38285931	Systemic therapy of brain metastases.
Q47585577	Systems Biology: a new hope for drug discovery?
Q90324481	Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
Q38066235	Systems biology technologies enable personalized traditional Chinese medicine: a systematic review
Q54627325	Systems biology-embedded target validation: improving efficacy in drug discovery.
Q58765906	T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring Mutations
Q40012030	TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer
Q34345632	TAGCNA: a method to identify significant consensus events of copy number alterations in cancer
Q35525917	TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
Q42286893	TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling
Q28393844	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Q34100276	TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Q45286133	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation
Q36285249	TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice
Q41959361	TKIs in NSCLC: the down of a new era?
Q38853578	TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib
Q52317261	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.
Q42259718	TRAIL apoptotic pathway-targeted therapies for NSCLC.
Q39373269	TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling
Q34137429	TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma
Q36836799	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia
Q36956724	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer
Q36430761	Tailor-made chemotherapy for non-small cell lung cancer patients
Q35927501	Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Q37851009	Taming the dragon: genomic biomarkers to individualize the treatment of cancer.
Q38669277	Target Therapy in Lung Cancer
Q34898454	Target therapies in lung cancer
Q42582783	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation
Q42328292	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer
Q90672582	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Q38930362	Targeted Therapies for Lung Cancer
Q34030379	Targeted Therapies in Lung Cancer
Q28083446	Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK
Q39192200	Targeted Treatment of Brain Metastases
Q38100162	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Q36616922	Targeted antitumour therapy--future perspectives
Q36920799	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives
Q36786085	Targeted cancer therapy: promise and reality
Q34356166	Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer
Q38956321	Targeted inhibition in tumors with ALK dependency
Q34683348	Targeted inhibition of kinases in cancer therapy
Q44992034	Targeted lung cancer therapies
Q26862516	Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges
Q37807159	Targeted molecular therapy in melanoma
Q36113026	Targeted molecular therapy of malignant gliomas
Q82494790	Targeted molecular therapy of malignant gliomas
Q37392703	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Q36128449	Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA
Q26738986	Targeted therapies and immunotherapy in non-small-cell lung cancer
Q35589492	Targeted therapies for advanced Ewing sarcoma family of tumors
Q35919642	Targeted therapies for cancer 2004.
Q36046241	Targeted therapies for gynecologic malignancies
Q54411624	Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Q36054970	Targeted therapies for lung cancer: clinical experience and novel agents
Q42431459	Targeted therapies for lung cancer: how did the game begin?
Q36150842	Targeted therapies for prostate cancer
Q49961144	Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.
Q38625550	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives
Q36934791	Targeted therapies in bladder cancer--an update
Q36051459	Targeted therapies in breast cancer.
Q27022852	Targeted therapies in development for non-small cell lung cancer
Q33606699	Targeted therapies in epithelial ovarian cancer
Q34878868	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action
Q36990546	Targeted therapies in non-small cell lung cancer
Q42845478	Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy
Q37956110	Targeted therapies: how personal should we go?
Q33807742	Targeted therapy for cancer: the gastrointestinal stromal tumor model
Q38390200	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Q37096910	Targeted therapy for squamous cell lung cancer
Q37204270	Targeted therapy in cancer
Q35207561	Targeted therapy in hepatocellular carcinoma
Q37246286	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
Q38042324	Targeted therapy in rare cancers--adopting the orphans
Q37290520	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
Q49956245	Targeted therapy of brain metastases: latest evidence and clinical implications.
Q37897792	Targeted therapy of non-small-cell lung carcinoma.
Q36026004	Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer.
Q37781113	Targeted therapy: an evolving world of lung cancer.
Q35671213	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Q36933081	Targeting ALK in neuroblastoma--preclinical and clinical advancements
Q38673845	Targeting ALK-rearranged non-small-cell lung cancer: an update
Q90133295	Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
Q27658951	Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Q33889144	Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells
Q40095585	Targeting EGFR in bladder cancer
Q37258827	Targeting EGFR in lung cancer: Lessons learned and future perspectives
Q37405633	Targeting EGFR resistance networks in head and neck cancer.
Q27027433	Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Q33750719	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Q27002155	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)
Q92035698	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Q34174883	Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?
Q53688274	Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia.
Q36898642	Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Q36429516	Targeting HER1/EGFR in cancer therapy: experience with erlotinib
Q35890128	Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum
Q37603214	Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Q42606238	Targeting IGF-1R: throwing out the baby with the bathwater?
Q36398758	Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Q37539304	Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Q42369856	Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer
Q29617685	Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Q33554884	Targeting PTPs with small molecule inhibitors in cancer treatment
Q37293656	Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
Q38608540	Targeting Signaling Transduction Pathways in Bladder Cancer
Q35575242	Targeting TACE-dependent EGFR ligand shedding in breast cancer
Q36580144	Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation
Q92693295	Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma
Q37435616	Targeting aromatase and estrogen signaling in human non-small cell lung cancer
Q38767073	Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy
Q37800284	Targeting cytoskeleton reorganisation as antimetastatic treatment.
Q36983136	Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer
Q36656097	Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?
Q37768460	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Q36613969	Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer
Q37789955	Targeting erbB receptors
Q64118764	Targeting exon 20 insertion mutations in non-small cell lung cancer
Q53078264	Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.
Q89533973	Targeting gallbladder cancer: a pathway based perspective
Q37068767	Targeting genomic alterations in squamous cell lung cancer
Q90481579	Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
Q37849013	Targeting mutant fibroblast growth factor receptors in cancer
Q34627751	Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice
Q39007950	Targeting of EGF-displayed protein nanoparticles with anticancer drugs.
Q38388217	Targeting of MEK in lung cancer therapeutics
Q35751013	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia
Q37847584	Targeting p27Kip1 protein: its relevance in the therapy of human cancer.
Q35987779	Targeting protein kinases in cancer therapy: a success?
Q37600910	Targeting the EGF receptor ectodomain in the context of cancer
Q39047294	Targeting the EGFR T790M mutation in non-small-cell lung cancer
Q34246558	Targeting the EGFR signaling pathway in cancer therapy
Q91329983	Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
Q37792116	Targeting the MET oncogene in cancer and metastases.
Q37265126	Targeting the PI3-kinase/Akt/mTOR signaling pathway
Q29618155	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Q33584823	Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe
Q37485865	Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.
Q37076172	Targeting the epidermal growth factor receptor in high-grade astrocytomas
Q36858198	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Q37990044	Targeting the epidermal growth factor receptor in solid tumor malignancies.
Q36564975	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.
Q90138425	Targeting the evolution of drug resistance in lung cancer
Q37863629	Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors
Q37862077	Targeting the human EGFR family in esophagogastric cancer
Q41830456	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Q41825773	Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
Q36472432	Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays
Q35876022	Technology platforms for pharmacogenomic diagnostic assays
Q35007976	Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study
Q36077604	Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Q36246336	Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
Q64916419	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.
Q36280333	Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
Q36587373	The 5 stages of biotechnology management
Q42143312	The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer
Q47655278	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Q36197375	The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
Q35208501	The BATTLE to personalize lung cancer prevention through reverse migration
Q34275011	The BATTLE trial: personalizing therapy for lung cancer
Q27010154	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Q35800375	The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients
Q34763495	The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Q36939336	The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
Q49544424	The Dawning of Translational Breast Cancer: From Bench to Bedside.
Q64055489	The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma
Q37026204	The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
Q49887941	The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Q36154748	The E3 ubiquitin ligase RNF135 regulates the tumorigenesis activity of tongue cancer SCC25 cells
Q92640668	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Q58605631	The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer
Q38201344	The EGFR family: not so prototypical receptor tyrosine kinases
Q40158764	The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines
Q37365512	The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China
Q38598710	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
Q37888326	The EMT regulator slug and lung carcinogenesis
Q54498075	The ERBB network: at last, cancer therapy meets systems biology.
Q37135372	The ERBB3 receptor in cancer and cancer gene therapy
Q40701318	The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials
Q36095650	The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.
Q37257613	The ErbB kinase domain: structural perspectives into kinase activation and inhibition
Q52673453	The Evolving Landscape of Brain Metastasis.
Q35835931	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer
Q39829525	The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
Q35608617	The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
Q34558080	The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Q35702309	The Impact of Coexisting Asthma, Chronic Obstructive Pulmonary Disease and Tuberculosis on Survival in Patients with Lung Squamous Cell Carcinoma
Q28067196	The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer
Q36280050	The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
Q46861636	The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).
Q39015512	The Importance of Biopsy in the Era of Molecular Medicine
Q35778529	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations.
Q39752575	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Q34459097	The MAPK pathway across different malignancies: a new perspective
Q34173500	The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Q38679301	The Microenvironment of Lung Cancer and Therapeutic Implications
Q35078950	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects
Q41043732	The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target
Q97569221	The National Lung Matrix Trial of personalized therapy in lung cancer
Q36316643	The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer
Q54388246	The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing.
Q33699378	The PIK3CA gene as a mutated target for cancer therapy
Q37838120	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example
Q58781611	The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
Q30009944	The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor
Q36535465	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Q39316449	The Role of ErbB Receptors in Infection
Q37335920	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
Q92830541	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers
Q38199934	The Role of STAT3 in Non-Small Cell Lung Cancer
Q37189951	The Role of the NF-kappaB Transcriptome and Proteome as Biomarkers in Human Head and Neck Squamous Cell Carcinomas
Q24649549	The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Q49963088	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Q38994746	The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors
Q37689252	The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).
Q38768030	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
Q30978835	The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data
Q64062553	The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Q42378470	The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
Q40439596	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
Q38418344	The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells
Q37397842	The aqueous extract of Brucea javanica suppresses cell growth and alleviates tumorigenesis of human lung cancer cells by targeting mutated epidermal growth factor receptor
Q37709481	The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations
Q36533669	The bioinformatics analysis of miRNAs signatures differentially expressed in HER2(+) versus HER2(-) breast cancers
Q49826396	The biology and management of non-small cell lung cancer.
Q36780601	The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases.
Q34342864	The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2.
Q34276557	The cellular origin for malignant glioma and prospects for clinical advancements
Q37871875	The challenges of integrating molecular imaging into the optimization of cancer therapy.
Q39134733	The changing landscape of clinical trial and approval processes in China.
Q39037647	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century
Q92644598	The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
Q28268061	The concept of synthetic lethality in the context of anticancer therapy
Q37077933	The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
Q34622547	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Q50050305	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI.
Q38907580	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
Q38233179	The diagnosis and treatment of brain metastases in EGFR mutant lung cancer.
Q90843191	The diagnosis of non-small cell lung cancer in the molecular era
Q26781159	The distinctive nature of adenocarcinoma of the lung
Q90728910	The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis
Q39425405	The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model.
Q86183346	The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects
Q35164824	The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review
Q39314771	The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
Q53165144	The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.
Q99365521	The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
Q37996424	The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
Q64078507	The emerging role of cell-free DNA as a molecular marker for cancer management
Q90481899	The emerging role of circulating tumor cells in cancer management
Q35076292	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Q34343043	The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
Q42643276	The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Q92221532	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Q38697702	The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells
Q40323538	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events
Q35196749	The epidermal growth factor receptor (EGRF) in lung cancer
Q35876412	The epidermal growth factor receptor as a target for gastrointestinal cancer therapy
Q34692233	The epidermal growth factor receptor family: biology driving targeted therapeutics
Q36268324	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
Q55147369	The era of precision oncogenomics.
Q44486103	The estimation of tumor cell percentage for molecular testing by pathologists is not accurate
Q37953478	The evolution of phase I trials in cancer medicine: a critical review of the last decade
Q34852043	The evolving genomic classification of lung cancer
Q37046861	The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma
Q37389768	The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
Q30539397	The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
Q36606755	The future in diagnosis and staging of lung cancer. Molecular techniques
Q38151562	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Q33389608	The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population
Q36605965	The genetics of health
Q41891513	The genomics of lung adenocarcinoma: opportunities for targeted therapies
Q35124798	The global landscape of intron retentions in lung adenocarcinoma
Q39648363	The hominoid-specific oncogene TBC1D3 activates Ras and modulates epidermal growth factor receptor signaling and trafficking
Q34057608	The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain
Q29619884	The impact of O2 availability on human cancer
Q90532509	The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma
Q36872857	The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma
Q26741041	The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis
Q64098196	The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures
Q36303828	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
Q37304354	The impact of genomic changes on treatment of lung cancer
Q38822314	The impact of immunohistochemistry on the classification of lung tumors.
Q36927984	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
Q37536556	The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
Q54271001	The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Q80833899	The impact of systems approaches on biological problems in drug discovery
Q38587521	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Q36040638	The importance of multidisciplinary team management of patients with non-small-cell lung cancer
Q39148511	The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations
Q84230583	The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma
Q52651786	The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance.
Q51689988	The inverted pyramid of biomarker-driven trials.
Q26823305	The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)
Q35568803	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression
Q40169126	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Q37976416	The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Q36348036	The mannose-binding lectin: a prototypic pattern recognition molecule
Q38726762	The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.
Q37022191	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Q39899686	The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
Q53512510	The molecular approach to diagnosis in lung cancer.
Q37703901	The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment
Q42583219	The need for an individual approach to lung cancer treatment
Q38292875	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
Q26998894	The next steps in next-gen sequencing of cancer genomes
Q37672566	The next-generation sequencing revolution and its impact on genomics
Q42360041	The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive
Q50237958	The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Q89497176	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Q35870933	The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Q36545226	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
Q45288154	The pathologist and EGFR in 2004: I like you, nor do it
Q54306159	The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer.
Q33693948	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
Q36752662	The pharmacogenetics research network: from SNP discovery to clinical drug response.
Q54560801	The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
Q45671065	The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer
Q34480697	The polynuclear platinum BBR3610 induces G2/M arrest and autophagy early and apoptosis late in glioma cells
Q57283047	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines
Q28072144	The possibility of clinical sequencing in the management of cancer
Q38632346	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer
Q37194315	The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer
Q89927858	The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer
Q92869196	The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas
Q41612540	The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Q28282889	The promise and perils of 'targeted therapy' of advanced ovarian cancer
Q38981780	The prospect of patritumab for treating non-small cell lung cancer
Q39272353	The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma
Q33725976	The quest to overcome resistance to EGFR-targeted therapies in cancer
Q35151853	The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas
Q54675285	The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Q92798542	The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
Q55439654	The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carbopla
Q34918878	The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors
Q38089953	The relevance of molecular diagnostics in the practice of surgical pathology.
Q38976895	The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro
Q50345037	The rise of genomic profiling in ovarian cancer.
Q39028181	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Q34349389	The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
Q37868445	The role of LKB1 in lung cancer
Q36704645	The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics
Q36561648	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
Q42095201	The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
Q33274011	The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target
Q35667688	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer
Q35043066	The role of epigenetics in personalized medicine: challenges and opportunities
Q26749110	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Q28397662	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer
Q35602147	The role of funding and policies on innovation in cancer drug development
Q51757887	The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
Q37715991	The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors
Q27021738	The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer
Q33779663	The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer
Q26825678	The role of obesity in gastrointestinal cancer: evidence and opinion
Q36463971	The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology
Q37430412	The role of pharmacogenetics and pharmacogenomics in improving translational medicine.
Q36536674	The role of pharmacogenetics in cancer therapeutics
Q39996855	The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Q28068169	The role of surgical intervention in lung cancer with carcinomatous pleuritis
Q38085500	The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
Q58741629	The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications
Q37085219	The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
Q39337947	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer
Q50782338	The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA.
Q82498098	The second wave in kinase cancer drugs
Q38704952	The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models
Q36839141	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors
Q26746895	The steady progress of targeted therapies, promising advances for lung cancer
Q44968164	The story of gefitinib, an EGFR kinase that works in lung cancer
Q35256540	The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Q89456689	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Q47214772	The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.
Q96231168	The top 100 cited articles in lung cancer - a bibliometric analysis
Q36446457	The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma
Q36354852	The transcriptional landscape and mutational profile of lung adenocarcinoma.
Q33772611	The translation of cancer genomics: time for a revolution in clinical cancer care
Q43128868	The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine
Q28534476	The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner
Q36928853	The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer
Q37177597	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations
Q87345449	The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer
Q35829847	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
Q33689655	The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas
Q83153095	The wind of change in the therapy of lung cancer
Q37755154	Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates
Q48100116	Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.
Q26824717	Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors
Q37632230	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications
Q28187576	Therapeutic approaches in arterial thrombosis
Q36429446	Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist
Q38172182	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks
Q27011293	Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer
Q35986801	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Q36158717	Therapeutic targeting of receptor tyrosine kinases in lung cancer
Q35976350	Therapeutic targets for antimetastatic therapy
Q36562233	Therapeutic targets in melanoma: map kinase pathway
Q35918439	Therapy for recurrent malignant glioma in adults
Q40462770	Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.
Q33740707	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Q92134589	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Q33302913	Thirty years into the genomics era: tumor viruses led the way.
Q50133191	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.
Q54570755	Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Q39090203	Three-color crystal digital PCR.
Q39813810	Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death
Q39290667	Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance
Q36050719	Throwing new light on lung cancer pathogenesis: updates on three recent topics
Q51750277	Thymosin alpha1 as a chemopreventive agent in lung and breast cancer.
Q35076227	Thyroid cancer: emerging role for targeted therapies
Q36065174	Thyroid transcription factor-1 expression is significantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in Chinese patients with lung adenocarcinoma.
Q43056665	Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Q58128825	Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?
Q53313789	Timeline: Chemotherapy and the war on cancer.
Q36141341	Tissue biomarkers for prostate cancer radiation therapy
Q34323926	Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.
Q37586979	Tissue specificity in the nuclear envelope supports its functional complexity.
Q34006509	Tissue-specific gene expression templates for accurate molecular characterization of the normal physiological states of multiple human tissues with implication in development and cancer studies
Q37109569	Tobacco Smoking and Lung Cancer: Perception-changing facts
Q39784247	Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice
Q37701499	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
Q40393934	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value
Q36472802	Toward personalized cancer nanomedicine - past, present, and future
Q37972865	Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies
Q35897673	Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway
Q34978252	Towards personalized therapy for patients with glioblastoma
Q42178081	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer
Q35889315	Tracking Down Response and Resistance to TRK Inhibitors
Q37688667	Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
Q30436756	Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor
Q33306709	Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations
Q24653386	Transcriptome sequencing to detect gene fusions in cancer
Q58116294	Transcriptomic and functional network features of lung squamous cell carcinoma through integrative analysis of GEO and TCGA data
Q51733149	Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.
Q93188555	Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations
Q22241760	Translatability scoring in drug development: eight case studies
Q35694365	Translating cancer 'omics' to improved outcomes
Q36411676	Translating genomic biomarkers into clinically useful diagnostics
Q36354845	Translating genomic information into clinical medicine: lung cancer as a paradigm
Q37127235	Translating insights from the cancer genome into clinical practice
Q38114641	Translating next generation sequencing to practice: opportunities and necessary steps
Q43010001	Translating research into cancer molecular diagnostics and patents
Q34344855	Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective
Q24806201	Translation research: from accurate diagnosis to appropriate treatment
Q42922307	Translational Bioinformatics Approaches to Drug Development
Q38257126	Translational research in oncology--10 years of progress and future prospects
Q46544726	Translational research: the full cycle
Q35977396	Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor.
Q37392560	Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
Q43195737	Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress.
Q34494115	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Q37698613	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
Q38739807	Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer
Q50104127	Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.
Q40244548	Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor
Q35623614	Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
Q37011144	Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Q35667817	Treatment of advanced non small cell lung cancer
Q59872738	Treatment of brain metastasis from lung cancer
Q36185627	Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
Q87296355	Treatment of non-small cell lung cancer, advanced disease, with erlotinib in 2(nd) and 3(rd) lines. Two cases report
Q37354440	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Q37218978	Treatment of recurrent metastatic head and neck cancer: focus on cetuximab
Q53547530	Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.
Q36412597	Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
Q35583860	Treatment of unresectable and metastatic cutaneous squamous cell carcinoma
Q92895800	Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China
Q40071770	Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro
Q95282127	Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
Q36038408	Trial Watch: Monoclonal antibodies in cancer therapy
Q56932681	Trial watch: Monoclonal antibodies in cancer therapy
Q35970324	Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
Q24564024	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future
Q37204363	Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
Q34041747	Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation
Q37594358	Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
Q36747692	Triple-negative breast cancer: therapeutic options
Q36048159	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Q36439444	Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Q37548937	Tumor dormancy and metastasis.
Q36616513	Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth
Q36196817	Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Q35584773	Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer
Q97538366	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Q38192631	Tumor heterogeneity in the clinic: is it a real problem?
Q38390044	Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients
Q91774076	Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Q45204330	Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting
Q37021940	Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
Q39839864	Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.
Q89579304	Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study
Q58599910	Tumour-targeting bacteria engineered to fight cancer
Q89651597	Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Q35896601	Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer
Q36022297	Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer
Q26741318	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Q46590868	Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology
Q37712380	Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma.
Q37894095	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Q35908430	Tyrosine kinase inhibitors in lung cancer
Q36977823	Tyrosine kinase inhibitors in pediatric malignancies
Q34983846	Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
Q37408903	Tyrosine phosphorylation: thirty years and counting
Q92840636	UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/β-catenin signaling pathway
Q58577633	USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
Q39962704	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers.
Q36185551	Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.
Q48128121	Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
Q39002233	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression
Q46915997	Understanding and targeting resistance mechanisms in NSCLC.
Q34088424	Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Q27691330	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model
Q28546245	Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors
Q52648399	Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
Q46787342	Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
Q37039734	Unifying electrostatic mechanism for phosphates and sulfates in cell signaling
Q33833942	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
Q81831688	Unique issues in the development of "targeted" antineoplastic pharmaceutical agents
Q40344816	Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma
Q36173303	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Q60044591	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
Q37443898	Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.
Q36429911	Update in lung cancer 2005.
Q36796569	Update in lung cancer 2006
Q35667802	Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
Q61810147	Update on emerging biomarkers in lung cancer
Q50802132	Update on epidermal growth factor receptor inhibitor development in lung cancer.
Q38237463	Update on systemic therapy of advanced non-small-cell lung cancer
Q37721218	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
Q44701539	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Q89485969	Upfront radiosurgery plus targeted agents followed by active brain control using radiosurgery delays neurological death in non-small cell lung cancer with brain metastasis
Q91845232	Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome
Q48604114	Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Q47564108	Urine test for EGFR analysis in patients with non-small cell lung cancer
Q37779308	Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment
Q33859472	Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy
Q89560168	Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients
Q37630180	Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.
Q37269473	Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
Q57556407	Use of genome-wide high-throughput technologies in biomarker development
Q36369836	Use of genomic signatures in therapeutics development in oncology and other diseases
Q30585673	Use of multiple imputation to correct for bias in lung cancer incidence trends by histologic subtype
Q34003351	Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Q27022535	Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review
Q52723939	Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor.
Q54586663	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
Q24813486	Ushering in the new toxicology: toxicogenomics and the public interest
Q55182205	Using Regularization to Infer Cell Line Specificity in Logical Network Models of Signaling Pathways.
Q28476059	Using expression and genotype to predict drug response in yeast
Q35829133	Using germ-line genetic variation to investigate and treat cancer
Q31038214	Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.
Q34474427	Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer.
Q34175045	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
Q35602598	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
Q37354097	Using the theory of coevolution to predict protein-protein interactions in non-small cell lung cancer.
Q38679628	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Q54390545	Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung.
Q37238134	Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research
Q37301478	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab
Q37393004	VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy
Q52803546	Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients.
Q89985173	Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations
Q41906700	Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens
Q92989775	Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
Q54118788	Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor.
Q41331019	Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations
Q34231456	Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells
Q35663913	Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer
Q80731960	Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma
Q48502619	Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer.
Q34903217	Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis
Q87928043	Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma
Q37177871	Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
Q38016190	Vandetanib for the treatment of lung cancer
Q39203869	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Q39218984	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
Q42598308	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Q38731617	Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays
Q36615850	Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
Q35456811	Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial.
Q36691776	Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy
Q35122066	Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.
Q35387710	Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity
Q57521562	Visceral obesity, metabolic syndrome, insulin resistance and cancer
Q36553854	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib
Q37280018	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression
Q37001330	Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1
Q36427381	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Q35927471	What are the reasons for negative phase III trials of molecular-target-based drugs?
Q34213994	What are we learning from the cancer genome?
Q38312059	What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?
Q46787079	What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?
Q48639219	What is the future for cancer clinical trials?
Q48241759	What is the potential of nanolock- and nanocross-nanopore technology in cancer diagnosis?
Q81352782	What oncologists need and require from nuclear medicine
Q24812087	When clinical trials are compromised: a perspective from a patient advocate
Q36496065	Where next for gefitinib in patients with lung cancer?
Q36610132	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Q44340382	Which drugs for which patients?
Q38222703	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Q43071284	Who will take up the gauntlet? Challenges and opportunities for systems biology and drug discovery
Q28269291	Whole-genome analysis informs breast cancer response to aromatase inhibition
Q48431386	Why Cancer matters.
Q33304557	Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?
Q35929119	Will tomorrow's medicines work for everyone?
Q37952291	Winning the arms race by improving drug discovery against mutating targets
Q34876177	Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.
Q38113540	Worldwide trend of increasing primary adenocarcinoma of the lung
Q36568760	Worldwide trends in lung cancer pathology
Q47097774	Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement
Q88682201	Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance
Q41281151	YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells
Q37829768	Year in review 2010: interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer
Q37624912	Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept
Q42690204	Young cancer researchers rewarded
Q36146882	ZD6474--clinical experience to date
Q80403956	["Targeted Therapies" in NSCLC - present and future]
Q54329437	[A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients].
Q55436763	[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Q55020044	[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Q64884192	[Anatomy, biology and concepts, pertaining to lung cancer stage classification].
Q79317745	[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma]
Q55464970	[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Q55464335	[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Q53340641	[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Q53520768	[Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].
Q54389938	[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].
Q54611055	[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma].
Q55437669	[Development of Precision Medicine in the Surgical Treatment of Lung Cancer].
Q54584671	[Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
Q53654923	[EGF receptor blockade with monoclonal antibodis and so-called "small molecules"].
Q49958940	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].
Q54482790	[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
Q54282828	[Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis].
Q54169610	[Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer].
Q55465317	[Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines].
Q79761419	[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]
Q84170796	[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer]
Q55432482	[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
Q64941333	[Lung cancer in women: a different entity?].
Q80294340	[Molecular diagnosis and response prediction to anti-tyrosine kinase receptors in oncology]
Q63979899	[Molecular diagnostics of lung cancer for treatment stratification]
Q80606168	[Molecular high throughput research in prostate carcinoma]
Q54262588	[Molecular targeted therapies and cytotoxics: Friends or foes?].
Q82663591	[Multi-targeting drugs and multi-drug targeting in metastatic renal cell carcinoma. Concept of co-inhibition of the epidermal growth]
Q80212282	[New biological treatments for lung cancer]
Q81596236	[New therapeutic approaches in glioblastomas]
Q87254396	[Personalized targeted therapy for lung cancer]
Q54164031	[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Q51057061	[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Q54602050	[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].
Q54177645	[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Q89862647	[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer]
Q81891643	[Targeted biotherapies in digestive oncology: a new era in therapeutic management?]
Q54176392	[Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].
Q55427171	[The detection methods of EGFR mutations in non-small cell lung cancer].
Q80737378	[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?]
Q80149575	[Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies]
Q55020040	[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
Q54484638	[Translational research and diagnostics in lung cancer].
Q54337306	[Treatment progress for EGFR wild-type advanced non-small cell lung cancer].
Q83901136	[Tyrosine kinase inhibitors in oncology]
Q35088202	[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients
Q53340770	c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells.
Q35997750	c-kit expression in adenocarcinomas of the lung.
Q38304521	hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
Q34729796	mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
Q39165050	mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy
Q33774131	miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met
Q38366840	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
Q34136203	miRNA expression profiling of lung adenocarcinomas: correlation with mutational status
Q33412928	nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer
Q39373570	p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway
Q47136556	p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category
Q40124869	s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis
Q40074891	siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells.
Q46707269	siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma
Q51512508	therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Q64884710	xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
Q38922926	γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer

P356	DOI	10.1056/NEJMOA040938
P3181	OpenCitations bibliographic resource ID	63134
P698	PubMed publication ID	15118073

P50	author	David C. Christiani	Q30069760
		Daniel Haber	Q5217393
P2093	author name string	Daphne W Bell
		Raffaella Sordella
		Ross A Okimoto
		Brian W Brannigan
		David N Louis
		Jeffrey G Supko
		Frank G Haluska
		Thomas J Lynch
		Patricia L Harris
		Sara M Haserlat
		Jeff Settleman
		Sarada Gurubhagavatula
P2860	cites work	Mutations of the BRAF gene in human cancer	Q27860760
P433	issue	21
P407	language of work or name	English	Q1860
P921	main subject	lung cancer	Q47912
P304	page(s)	2129-39
P577	publication date	2004-05-20
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
P478	volume	350

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

scientific article (publication date: 20 May 2004)

Reverse relations